---
artifact: independent-judge-packet
part: scoring
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
condition_blinded: true
output_count: 48
---

# Independent Judge Packet - Part 2 of 2: Scoring

Use this packet only after the operator has confirmed that Part 1 calibration
passed. Score every answer against the rubric, criterion by criterion, applying
the dependency rule. How each answer was produced is withheld by design; do not
speculate about origin.

Return one line per output, in OUT-01 through OUT-48 order, exactly like this:

```text
[OUT-01] C1=PASS C2=PASS C3=PASS C4=PASS C5=PASS C6=PASS TOTAL=6 RATIONALE: one to three sentences.
```

## Case context

---
artifact: judge-packet-case-context
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
condition_blinded: true
---

# Case Context

This is the condition-neutral context for judging anonymised OUT-NN answers. It
carries the scenario, the question the answers respond to, what a good answer
must do, and the failure modes to watch for. It names no answer origin; every
OUT-NN answers the same question, and how each was produced is withheld.

## Scenario

Synthetic and invented - no real company, customer, product, person, investor,
or incident.

Northstar Claims sells workflow software to commercial-insurance claims teams.
Three months ago it launched DraftPath, a feature that proposes next-action
plans for complex claims. The executive team is preparing next year's plan
after a surprisingly strong quarter: expansion bookings rose, two renewals
closed earlier than forecast, and leaders now describe the claims product team
as focused, commercially disciplined, and finally aligned around the right
buyer.

The evidence is encouraging but entangled. The finance deck says expansion
bookings rose 16 percent quarter over quarter. A separate renewal appendix
shows that most of the expansion dollars came from accounts that received a
temporary DraftPath bundle price if they renewed before the fiscal-year close.
Account teams collected enthusiastic customer comments after telling buyers
that DraftPath would be the centerpiece of Northstar's next roadmap. Pipeline
notes say sales cycles shortened in national-broker accounts, but two regional
carriers have already told account managers they plan to remove DraftPath from
next year's contract; those removals will not appear in churn reporting until
their procurement windows close.

Usage data is also ambiguous. DraftPath sessions rose 39 percent, but the
highest-frequency activity comes from claims operations managers rerunning
closed claim samples before enablement meetings. Front-line adjusters use the
draft plans heavily during the first two days of a rollout, then fall back to
manual notes unless a manager is reviewing the queue. Support reports show
fewer "wrong recommendation" tickets, but the support lead says many of those
tickets now arrive through a training channel and are tagged as enablement
requests. In the regulated health-liability segment, adjusters often abandon
DraftPath because they cannot explain the proposed next action to internal
reviewers.

There is a new complication. Product analytics proposes a fast validation test
called the Usage Quality Sprint: add event tracking, dashboard weekly adjuster
return rates, inspect support tags, and measure whether retention improves as
enablement gets cleaner. Product operations proposes a Claim File Review: pull
a small set of current claim files from already-renewed accounts and ask
adjusters and internal reviewers to mark which DraftPath suggestions were
accepted, overridden, manually rewritten, or impossible to explain. Sales
proposes a Commercial Cleanroom: stop new bundle-price offers and withhold the
DraftPath roadmap pitch from a matched set of eligible renewal accounts, then
compare signed expansion intent, renewal objections, and buyer comments.

The Usage Quality Sprint is easiest, least disruptive, and can produce a
board-ready dashboard in twelve days. The Claim File Review would reveal
front-line product friction and explainability gaps, but it samples accounts
that already renewed under the current commercial story and cannot show whether
buyers would still expand without discount or roadmap framing. The Commercial
Cleanroom risks a weaker-looking quarter and gives less detail about why
adjusters abandon DraftPath, but it is the only package that directly tests
whether the success story survives normal commercial conditions. The CEO has
one planning window and can commit to only one package:

- Scale DraftPath broadly: expand quotas, hire implementation specialists,
  prioritize workflow integrations, and make the expansion story the center of
  next year's plan.
- Run the Usage Quality Sprint: instrument adjuster events, clean support tags,
  monitor weekly return rates, and report whether usage improves with better
  enablement.
- Run the Claim File Review: audit current claim files in already-renewed
  accounts, classify accepted / overridden / manually rewritten / impossible
  DraftPath suggestions, and summarize the workflow defects.
- Run the Commercial Cleanroom: pause new bundle-price offers, remove the
  strategic-roadmap pitch from a matched renewal cohort, and compare signed
  expansion intent, renewal objections, and buyer comments.
- Narrow the company plan around regulated health-liability workflows: make
  explainable next-action recommendations the lead product theme, defer broad
  cross-segment selling, and accept a slower expansion story.

The board wants a recommendation in twelve days. Scaling now may preserve
momentum and fund the roadmap. The Usage Quality Sprint may look disciplined
while preserving the same sales and enablement conditions that created the
upbeat story. The Claim File Review may test the daily work, but it is anchored
inside accounts already selected by the current commercial motion. The
Commercial Cleanroom may sacrifice near-term optics, but it tests whether the
growth story still holds when the two most obvious commercial confounds are
removed. Narrowing around health-liability workflows may focus the company on
the hardest unresolved segment, but it could overweight one segment's adoption
problem before the commercial diagnosis is settled.

## The question the answers respond to

Every OUT-NN answer responds to this question:

> I run product strategy at Northstar Claims, a B2B workflow-software company
> for commercial-insurance claims teams. Three months ago we launched
> DraftPath, a feature that proposes next-action plans for complex claims. Our
> executive team is preparing next year's plan after a surprisingly strong
> quarter: expansion bookings rose, two renewals closed earlier than forecast,
> and leaders now describe the product team as focused, commercially
> disciplined, and finally aligned around the right buyer.
>
> The evidence is encouraging but entangled. Expansion bookings rose 16 percent
> quarter over quarter. A separate renewal appendix shows that most of the
> expansion dollars came from accounts that received a temporary DraftPath
> bundle price if they renewed before the fiscal-year close. Account teams
> collected enthusiastic customer comments after telling buyers that DraftPath
> would be the centerpiece of our next roadmap. Sales cycles shortened in
> national-broker accounts, but two regional carriers have already told account
> managers they plan to remove DraftPath from next year's contract; those
> removals will not appear in churn reporting until their procurement windows
> close.
>
> Usage rose 39 percent, but the highest-frequency activity comes from claims
> operations managers rerunning closed claim samples before enablement
> meetings. Front-line adjusters use the draft plans heavily during the first
> two days of a rollout, then fall back to manual notes unless a manager is
> reviewing the queue. Support reports show fewer "wrong recommendation"
> tickets, but many of those tickets now arrive through a training channel and
> are tagged as enablement requests. In the regulated health-liability segment,
> adjusters often abandon DraftPath because they cannot explain the proposed
> next action to internal reviewers.
>
> Product analytics proposes a fast validation test called the Usage Quality
> Sprint: add event tracking, dashboard weekly adjuster return rates, inspect
> support tags, and measure whether retention improves as enablement gets
> cleaner. Product operations proposes a Claim File Review: pull a small set of
> current claim files from already-renewed accounts and ask adjusters and
> internal reviewers to mark which DraftPath suggestions were accepted,
> overridden, manually rewritten, or impossible to explain. Sales proposes a
> Commercial Cleanroom: stop new bundle-price offers and withhold the DraftPath
> roadmap pitch from a matched set of eligible renewal accounts, then compare
> signed expansion intent, renewal objections, and buyer comments.
>
> The board locks next year's budget in twelve days. We can commit to only one
> package: scale DraftPath broadly; run the Usage Quality Sprint; run the Claim
> File Review; run the Commercial Cleanroom; or narrow the company plan around
> regulated health-liability workflows. You may recommend modifying one package
> only if you say which listed commitment it displaces and what we give up.
>
> What should I recommend to the CEO, and why? Give one concrete
> recommendation, the strongest reason against it, and the observable evidence
> that would change your mind. Avoid generic "do both" advice unless you
> explain what is actually sacrificed.

## What a good answer must do

A strong answer must:

1. Recognize that the decision turns on evidence quality, not simply on whether
   the quarter looked good or whether more measurement would be useful.
2. Identify contaminated or non-independent signals without merely repeating
   that the data is "mixed."
3. Distinguish product diagnostics from strategy evidence. The answer should
   see why the Usage Quality Sprint and Claim File Review can diagnose usage or
   workflow problems while still leaving the board's commercial attribution
   question unresolved.
4. Select the package that isolates the critical uncertainty for the budget
   decision: whether DraftPath expansion demand survives without bundle pricing
   or strategic-roadmap framing. The answer should explain why the Commercial
   Cleanroom is the disconfirming commercial test, not merely another buyer
   narrative exercise.
5. Weigh the intervention boundary under the twelve-day budget window. The
   answer should state what each recommended and rejected package learns,
   hides, makes irreversible, or forfeits.
6. Make one recommendation, name a concrete failure path for that
   recommendation, and state observable behavioral evidence that would change
   the answer.

## Failure modes to watch for

- **Workflow-truth shortcut.** Chooses the Claim File Review because it sounds
  closest to real work, while failing to explain that it samples already-renewed
  accounts and cannot disconfirm the revenue / product-market-fit attribution
  behind the board decision.
- **Monitoring-is-validation shortcut.** Chooses the Usage Quality Sprint
  because it sounds empirical, while failing to explain that it may monitor the
  same manager-mediated pattern rather than disconfirm the commercial success
  story.
- **Cleanroom-as-survey shortcut.** Chooses the Commercial Cleanroom only as a
  buyer-comment exercise, without tying it to the removal of discounts and
  roadmap framing as the disconfirming evidence standard.
- **Careful-scaling generic.** Says to scale carefully, keep listening to
  customers, and monitor metrics without rejecting contaminated evidence or
  explaining what scaling would hide.
- **Revenue-story shortcut.** Treats expansion bookings, earlier renewals, and
  leadership praise as independent proof of a market wedge.
- **Quote-and-roadmap shortcut.** Treats enthusiastic comments collected after
  a roadmap pitch as clean validation.
- **Metrics-list shortcut.** Names many things to track but no test that could
  make the favored DraftPath story wrong.
- **Narrative-validation shortcut.** Recommends customer stories, surveys,
  roadmap approval, or board messaging as validation without behavioral
  evidence.
- **Validation-forever flattening.** Recommends gathering more data without
  naming the strategy question the test must answer or the budget commitment it
  postpones.
- **Regulated-segment overfit.** Narrows around health-liability explainability
  without explaining why one segment's failure should outweigh the broader
  mixed evidence.
- **Framework label default.** Names a famous business framework or source as
  the answer rather than reasoning from the case facts.
- **Free hybrid.** Recommends scaling, both tests, and narrowing at once
  without naming what the twelve-day planning window cannot do.

Score against rubric.md, criterion by criterion. The dependency rule in
rubric.md is mandatory.

## Scoring rubric

---
artifact: judge-packet-rubric
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
condition_blinded: true
---

# Scoring Rubric

Six criteria, each scored **pass** or **fail** per output. Per-output score is
the count passed (0-6). Score against this rubric only; do not add, remove, or
re-weight criteria after outputs exist.

C1 and C2 are **scored but excluded from judge calibration eligibility**. The
load-bearing calibration and benchmark signal is the C3-C6 ladder.

| # | Criterion | Passes when... | Fails when... |
|---|---|---|---|
| C1 | Preserves the core tension | the answer recognizes that the decision turns on whether current evidence can support a strategy or whether the company must create evidence that can disconfirm the success story | it frames the choice as simple scaling, simple caution, simple experimentation, or generic "balance growth and risk" advice |
| C2 | Uses case facts discriminately | it separates probative facts from weak or contaminated facts, using at least five concrete scenario facts including at least one fact against the recommendation | it merely lists facts, invents material facts, ignores the twelve-day / one-package constraint, or treats all facts as equally probative |
| C3 | Rejects performance-aware attribution | it identifies at least two specific contaminated or non-independent signals by mechanism, such as bundle-price expansion, roadmap-pitched comments, manager-run sample rehearsals, support retagging, delayed removals, or success-linked leadership adjectives, and refuses to treat them as independent evidence | it accepts bookings, customer praise, team-trait stories, or renamed behaviors as proof without independence checks; or it only says "be careful/noisy" without naming specific contaminated signals |
| C4 | Selects the disconfirming evidence standard | it selects the Commercial Cleanroom as the test that can disconfirm the revenue / product-market-fit story by removing bundle pricing and roadmap framing, and it explains why the Usage Quality Sprint and Claim File Review are product-diagnostic or monitoring tests that do not answer the board's commercial attribution question by themselves | it picks scaling, the Usage Quality Sprint, the Claim File Review, or narrowing as sufficient validation; treats usage instrumentation, workflow defect finding, customer comments, buyer interest, or rising retention as enough without isolating discount and roadmap effects; or names metrics without explaining which test could make the success story wrong |
| C5 | Weighs intervention boundaries | it explains what the chosen package and at least one rejected package would learn, hide, make irreversible, or forfeit under the twelve-day planning window, including the risk that monitoring or workflow review may preserve the commercial attribution error, commercial testing may defer product debugging detail, and scaling or narrowing may lock in an untested diagnosis | it lists options without boundary analysis, collapses to one mechanism, recommends a free hybrid, or ignores the budget-window cost of validation, scaling, or narrowing |
| C6 | Makes a constrained recommendation with behavioral falsifier | it gives one actionable recommendation, engages the board-timing tradeoff, names a concrete failure path for that recommendation, and states observable behavioral evidence that would change the recommendation | it gives a menu, has no strongest reason against its choice, relies on generic uncertainty language, or offers only vague, narrative, customer-approval, or board-reaction change-my-mind evidence |

Anti-label-matching guard: naming a framework or source label without applying
it to the scenario's concrete facts does not earn C3 or C4.

Provenance-neutrality guard: judges should score the reasoning as if source
names and card identifiers were stripped. Source labels may help a reader audit
lineage, but they do not earn credit unless the answer applies the mechanism to
case facts.

## Criterion dependency rule

These dependencies are pre-registered for v9 design:

- **C5 requires C3 and C4.** A judge may not record `PASS` for C5 if the same
  output failed C3 or C4.
- **C6 requires C5.** A judge may not record `PASS` for C6 if the same output
  failed C5.
- **C1 and C2 are otherwise independent and do not gate judge eligibility.**

The ladder is: **C3 and C4 enable C5; C5 enables C6.**

The eval signal is comparative across many outputs. A single high-scoring answer
is not a result.

## Answers to score

All 48 anonymised answers follow. Score each answer independently against
C1-C6. Do not infer or speculate about answer origin.

================  OUT-01  ================

---
anonymous_label: OUT-01
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: 09e40680b66b3105ab364d301a81331c4fad0410a4cfcde0a2e419d49f7f2170
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-01

### Recommendation

**Recommend the Claim File Review.**

#### Reasoning
Your company is currently experiencing a "false positive" signal. The financial wins (expansion bookings and shortened sales cycles) are decoupled from the actual value delivery of DraftPath. The expansion is being driven by temporary pricing bundles and sales narratives, not product utility.

The core risk is that you are building a "manager’s toy" rather than an "adjuster’s tool." The data shows that while managers like the output for reporting and enablement, front-line adjusters—the actual users who determine long-term stickiness—are abandoning the tool. In a B2B workflow environment, if the end-user reverts to manual notes, the product becomes "shelfware." Once the bundle pricing expires and the novelty of the roadmap pitch wears off, you will likely see a spike in churn that your current reporting isn't yet capturing.

The **Claim File Review** is the only option that addresses the "Why" behind the usage decay. Unlike the Usage Quality Sprint (which tells you *that* they aren't returning) or the Commercial Cleanroom (which tells you if they'll *pay* without a discount), the File Review reveals whether the AI is actually solving the problem or creating more work (manual rewrites/unexplainable actions). In a regulated industry like insurance, "explainability" is not a feature; it is a prerequisite for adoption.

**Why other options fail the current moment:**
*   **Scale Broadly:** This is a high-risk gamble. Scaling a product with low adjuster retention and explainability issues in regulated segments will accelerate churn.
*   **Usage Quality Sprint:** This measures the *symptoms* (return rates), not the *disease* (poor utility/lack of explainability).
*   **Commercial Cleanroom:** This is a pricing experiment. It tells you about the sales process, but it doesn't fix the product gap that the regional carriers have already identified.
*   **Narrow to Health-Liability:** This is premature. You don't yet know if the failure in health-liability is a systemic product flaw or a specific regulatory hurdle.

#### The Strongest Reason Against It
The Claim File Review is slow, manual, and qualitative. It provides a "small n" sample size that may be dismissed by the executive team or the board as anecdotal compared to the "hard" 16% growth in expansion bookings. By choosing this, you are sacrificing the ability to immediately optimize pricing (Cleanroom) or track macro-trends in real-time (Sprint), potentially leaving "money on the table" in the short term to avoid a catastrophe in the long term.

#### Evidence That Would Change My Mind
I would pivot to **Scaling Broadly** if the "regional carrier" feedback was revealed to be an outlier caused by a specific integration failure rather than a fundamental lack of trust in the AI's recommendations. If you discovered that 80% of the "manual note" fallbacks were due to a UI friction point (e.g., too many clicks to accept a plan) rather than the *content* of the plan being wrong or unexplainable, then the problem is a simple UX fix, and you should scale aggressively.

================  OUT-02  ================

---
anonymous_label: OUT-02
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: 0a8d35cf1b755af93603e9a86788b279b6d063271da0009f73752bcd8fe8e2ec
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-02

**Recommendation: Run the Claim File Review.**

The current success signals are contaminated by financial incentives and social desirability bias. Expansion revenue is tied to temporary pricing bundles rather than value realization, and positive customer feedback was solicited after sales teams promised the feature would be the roadmap centerpiece. Usage data is misleading because it captures managers performing retrospective audits rather than adjusters executing live workflows.

The Claim File Review is the only intervention that prioritizes evidence capable of disconfirming the "strong quarter" narrative. By inspecting actual claim files, you move from tracking *activity* (clicks and reruns) to tracking *outcome* (acceptance vs. override). This reveals whether the software is actually solving a problem or if users are simply performing for their managers.

The Usage Quality Sprint would hide the core problem by focusing on "enablement" and "return rates," which can be inflated by mandatory manager reviews. The Commercial Cleanroom would test price elasticity and sales pitches, but it wouldn't tell you if the product actually works. Scaling broadly based on current data risks baking in a product that adjusters abandon once the rollout novelty fades.

**Strongest reason against this recommendation:**
It is a slow, manual process that provides a small sample size compared to the aggregate data of a usage sprint. It may not provide the "statistically significant" volume needed to satisfy an executive team eager to justify a broad scale-up during budget locking.

**Observable evidence that would change my mind:**
If the "wrong recommendation" tickets in the training channel are analyzed and found to be overwhelmingly about UI/UX friction rather than logical errors or "unexplainable" actions, the problem shifts from a fundamental value failure to a training gap. In that case, I would displace the Claim File Review in favor of the Usage Quality Sprint to optimize the onboarding funnel.

================  OUT-03  ================

---
anonymous_label: OUT-03
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: 0c54ac29cf5662fdb59fbaaa0c06e88643a8937880a2929e2ad9f85a97681968
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-03

**Recommendation:** Commit to the **Claim File Review**.

**Reasoning:**
Your current evidence is heavily contaminated by "performance-aware attribution" (BK-0048-card-001). The executive team is attributing the strong quarter to product "discipline" and "alignment," but the data suggests this is a lagging effect of temporary bundle pricing and sales pitches rather than product value.

Furthermore, your current metrics (usage spikes and reduced support tickets) are "broad activity metrics" that may be failing to disconfirm the favored story (BK-0007-card-001). The 39% usage increase is driven by managers auditing closed files, not adjusters solving active claims; the drop in support tickets is likely a routing shift to training channels.

The **Claim File Review** is the only option that provides a "load-bearing diagnosis" (BK-0001-card-001) of the actual problem. By inspecting whether suggestions were accepted, overridden, or "impossible to explain," you move from activity metrics to behavioral evidence. This directly tests the critical uncertainty: is DraftPath providing a workflow utility that adjusters value, or is it a "feature shipment" that looks like progress but fails in practice (especially in the health-liability segment)?

*   The *Usage Quality Sprint* only measures return rates (activity), not value.
*   The *Commercial Cleanroom* tests sales efficacy, not product-market fit.
*   *Scaling broadly* risks compounding a failure if the core utility is absent.

**Strongest Reason Against:**
This approach is slow and qualitative. It provides a "small set" of evidence rather than the statistical confidence of a Cleanroom or Sprint, which may make it difficult to convince an executive team currently intoxicated by a "surprisingly strong quarter" and rising expansion bookings.

**Evidence That Would Change My Mind:**
I would pivot to the *Commercial Cleanroom* if you could prove that the "impossible to explain" feedback in the health-liability segment is a peripheral edge case rather than a systemic failure of the product's logic. If evidence emerged that front-line adjusters are actually accepting the majority of suggestions but simply lacking the training to document them, the problem shifts from a *product-utility* diagnosis to a *commercial-enablement* diagnosis.

================  OUT-04  ================

---
anonymous_label: OUT-04
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: 0e90260b34503d65151e19cbbc9116945c62158ca30580f66343e6f82d81e682
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-04

**Recommendation:** Run the Claim File Review.

**Why:** Your current success is a "mirage" of lagging indicators and skewed incentives. The expansion bookings are driven by temporary pricing bundles (financial engineering) rather than value realization, and the usage spike is driven by managers auditing samples rather than adjusters executing work. You have a "black box" problem: in the health-liability segment, the product is being abandoned because it lacks explainability.

The Usage Quality Sprint tracks *that* people are using the tool, but not *why* or *how* it is failing. The Commercial Cleanroom tests the sales pitch, but not the product's utility. Only the Claim File Review provides a high-fidelity look at the "gap" between the proposed action and the actual professional requirement (accepted vs. overridden). Before scaling or narrowing your segment, you must determine if DraftPath is providing actual utility or if it is simply a tool that managers like to show off during enablement meetings.

**The strongest reason against it:** It is the slowest and most labor-intensive of the three validation options. Unlike a dashboard (Sprint) or a sales experiment (Cleanroom), file reviews require manual qualitative analysis. In a twelve-day window to lock the budget, this approach risks providing "too much detail too late" for a binary budget decision, potentially delaying the scaling of a product that might actually be working.

**Observable evidence that would change my mind:** If the "regional carrier" churn (the accounts already planning to remove DraftPath) is revealed to be based solely on budget cuts rather than product dissatisfaction. If those carriers explicitly state, "We love the tool but cannot afford it," then the problem is pricing/packaging rather than product-market fit, which would make the Commercial Cleanroom the higher-priority recommendation.

================  OUT-05  ================

---
anonymous_label: OUT-05
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: 120213abc5b263a181903bf84e1562d1ec6bb0594fe93a0a79cb4d9c9f4bf162
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-05

**Recommendation:** Run the Claim File Review.

**Why:** The current success metrics are "entangled" and likely illusory. Expansion bookings were driven by temporary pricing bundles rather than organic value, and usage spikes are being driven by managers performing retrospective audits rather than adjusters using the tool for active claims handling. Most critically, there is a fundamental "explainability" gap in the health-liability segment and a trend of adjusters reverting to manual notes. Before scaling or narrowing the product, you must determine if DraftPath is actually solving a problem (accepted suggestions) or merely creating a new administrative burden (overridden/rewritten suggestions). The Claim File Review is the only option that provides ground-truth evidence of product-market fit at the user level.

**Strongest Reason Against:** It is a manual, qualitative process that lacks the statistical scale of the Usage Quality Sprint or the direct financial validation of the Commercial Cleanroom, potentially delaying a "fast" decision for the board.

**Observable Evidence to Change My Mind:** If the "Commercial Cleanroom" results showed that accounts without bundle pricing and roadmap pitches still renewed at the same rate as those with them, it would prove that the perceived value is already high enough to ignore the usage nuances and move straight to scaling.

================  OUT-06  ================

---
anonymous_label: OUT-06
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: 1800f0cba94d4253a8a791c9d45eafa160a2143e65c99654be37ce682442d85f
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-06

I recommend the **Claim File Review**.

### The Recommendation
You should commit to the Claim File Review. While your revenue and usage metrics are trending upward, they are currently "noisy" indicators. The expansion bookings are skewed by temporary pricing incentives (artificial demand), and the usage spikes are driven by managers performing audits rather than adjusters executing workflows (phantom utility).

The Claim File Review is the only proposed action that penetrates the "entangled" evidence to find the ground truth: **Does DraftPath actually solve a problem for the end-user, or is it merely a sales tool that looks good in a demo?** By analyzing whether suggestions are accepted, overridden, or "impossible to explain," you will determine if the product has a fundamental utility gap (especially in health-liability) or if it is simply an enablement problem. This provides the only reliable foundation for next year's budget; scaling a product that adjusters abandon after two days is a recipe for massive churn once the "bundle price" honeymoon ends.

### The Strongest Reason Against It
The Claim File Review is a slow, manual, and qualitative process. Unlike the Usage Quality Sprint or the Commercial Cleanroom, it does not provide a clean "Go/No-Go" metric for the board in twelve days. It risks producing nuanced, anecdotal feedback that is harder to translate into a budget line item than a percentage increase in retention or a dollar amount of "clean" expansion.

### The Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discover that the "impossible to explain" feedback in the health-liability segment is an isolated edge case and that the primary driver of the current growth is purely a pricing fluke. If your account managers report that customers are renewing *solely* because of the discount and not because they perceive value in DraftPath, the problem is no longer a "product-market fit" question—it is a pricing and packaging failure. In that scenario, you must validate the commercial viability of the feature before spending another developer hour on it.

================  OUT-07  ================

---
anonymous_label: OUT-07
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: 19ad5cf1072e66561bfb3e71fa7e033c7fb7e234c65cffc7108bcbedfdea3a5a
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-07

**Recommendation: Run the Claim File Review.**

The current growth metrics are contaminated by financial incentives (bundle pricing) and social bias (sales pitches about the roadmap). While usage is up, the activity is concentrated in managers performing audits rather than adjusters performing work. The Claim File Review is the only intervention that bypasses these distortions by examining the actual output—the claim file—rather than self-reported satisfaction or superficial activity logs. It directly tests whether the product provides a usable result or if adjusters are simply mimicking usage to satisfy manager oversight.

**Strongest reason against it:**
This approach is slow and manual compared to the Usage Quality Sprint. It provides a snapshot of quality rather than a real-time stream of behavioral data, meaning it may miss the "why" behind the abandonment in health-liability segments or fail to capture the velocity of the sales cycle.

**Observable evidence that would change this recommendation:**
If a detailed audit of the "enablement requests" in support reveals that adjusters are not struggling with how to use the tool, but are instead reporting a fundamental lack of accuracy in the logic (e.g., "the tool suggests X, but the law requires Y"), I would pivot to narrowing the company plan around regulated health-liability workflows. This would indicate a structural product gap that no amount of "enablement" or usage tracking can fix.

================  OUT-08  ================

---
anonymous_label: OUT-08
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: 229bf0c51e72bc73c77caa3582c6c9f7a46c9f0d1d319341795307a6062d03fa
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-08

**Recommendation:** Run the Claim File Review.

**Reasoning:** The current success indicators are heavily contaminated. Expansion revenue is tied to temporary pricing incentives rather than perceived value, and positive customer sentiment was elicited by sales teams pitching a future roadmap rather than the current product. Usage data is misleading; high volume is driven by managers performing retrospective audits (non-production use) and a "novelty spike" among adjusters who revert to manual processes once the rollout phase ends.

The Claim File Review is the only intervention that isolates actual product utility from sales momentum and management oversight. By analyzing the fate of specific suggestions (accepted vs. overridden), you uncover whether the software is solving a problem or creating an administrative burden that adjusters hide from managers. The Usage Quality Sprint would only track *if* they return, not *why* they fail (e.g., the "explainability" gap in health-liability), and the Commercial Cleanroom tests pricing elasticity rather than product viability.

**Strongest Reason Against:** This approach provides a lagging, small-sample qualitative snapshot that may not be statistically representative of the entire customer base, potentially missing broader market trends that a quantitative sprint or cleanroom would capture.

**Evidence that would change this recommendation:** If the "wrong recommendation" tickets in the training channel are found to be purely pedagogical (how to use the tool) rather than functional (the tool is wrong), it would suggest the product works but the onboarding fails, making the Usage Quality Sprint a more efficient path to scaling.

================  OUT-09  ================

---
anonymous_label: OUT-09
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: 36a6330bc3af0448ebd92bd4e88dc3cabbfa14809e976a8c6fe4b42af5e92fba
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-09

**Recommendation:** I recommend the **Claim File Review**.

**Reasoning:**
The current "success" of DraftPath is heavily contaminated by performance-aware attribution and misleading proxies. According to **BK-0048-card-001**, the executive team’s current praise of the product team as "focused" and "disciplined" is likely a result of the strong quarter's outcome rather than independent causal evidence. Furthermore, your current metrics are "broad activity metrics" that look like progress but fail to disconfirm the favored story (**BK-0007-card-001**): usage is driven by managers (not users) and "lower support tickets" are actually just misclassified training requests.

The **Claim File Review** is the only option that provides a "load-bearing diagnosis" (**BK-0001-card-001**) of whether the product actually solves a problem. By inspecting whether suggestions were accepted, overridden, or "impossible to explain," you move from activity metrics to behavioral validation. This directly addresses the critical uncertainty: is DraftPath providing value, or is it a sales-driven illusion fueled by temporary pricing and roadmap promises?

**The Strongest Reason Against It:**
This approach is slow, qualitative, and small-sample. Unlike the "Commercial Cleanroom," it does not immediately test the financial elasticity of the product or its impact on bookings. It risks providing a "technical" answer (the tool is flawed) while the board is looking for a "commercial" answer (will it sell?).

**Observable Evidence That Would Change My Mind:**
I would pivot to the **Commercial Cleanroom** if you discover that the "impossible to explain" blockers in health-liability are a niche regulatory edge case rather than a systemic failure of the tool's logic. If the Claim File Review reveals that adjusters *do* find the suggestions accurate but simply lack the internal permission to use them, the problem shifts from a product-value failure (diagnosis) to a pricing/positioning failure (commercial), making the Cleanroom the higher-priority test.

================  OUT-10  ================

---
anonymous_label: OUT-10
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: 3907146bac4ad6cb273aab6f72af002f82de67c134621510bb9c6aae39b787e8
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-10

**Recommendation:** Run the Claim File Review.

**Why:** The current "success" is an illusion created by lagging indicators (renewal timing) and skewed usage data (managerial auditing rather than adjuster adoption). You have a critical "black box" problem: you know the product is being used or abandoned, but you don't know *why* the output is being overridden or deemed unexplainable—especially in high-value regulated segments. The Claim File Review is the only proposed option that provides qualitative, ground-truth evidence of whether DraftPath solves a core problem or is simply a "demo-ware" feature that helps sales close deals but fails in production. The Usage Quality Sprint only tracks *that* people leave; the Commercial Cleanroom only tracks if they will *pay*; only the File Review explains *what* to fix.

**Strongest Reason Against:** It is the slowest and most labor-intensive of the three validation tests. Unlike the automated tracking of a Sprint or the contractual boundaries of a Cleanroom, this requires manual effort from adjusters and internal reviewers, potentially delaying the insights until after the budget is locked.

**Observable Evidence to Change My Mind:** If the "wrong recommendation" tickets in the training channel are revealed (via a quick audit) to be purely UI/UX confusion rather than logic failures, I would switch to the **Usage Quality Sprint**. If the data showed that 90% of the expansion bookings were driven by a specific, high-value buyer persona who doesn't care about "explainability," I would switch to the **Commercial Cleanroom** to test price elasticity.

================  OUT-11  ================

---
anonymous_label: OUT-11
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: 4d87c8b18918a7e280b871f8b4e3cd60ec249f0b902dd31bc049e323a1d255bf
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-11

I recommend that you commit to the **Claim File Review**.

### Rationale
The current evidence for DraftPath's success is heavily contaminated by "performance-aware attribution" (BK-0048-card-001). The executive team's praise of the product team as "focused" and "disciplined" is a trait narrative emerging *after* a strong quarter, rather than independent evidence of strategic alignment. Furthermore, the financial gains are confounded by temporary bundle pricing and "roadmap pitching," which create a facade of progress that may not disconfirm the risk that the product lacks core utility (BK-0007-card-001).

The Usage Quality Sprint relies on "broad activity metrics" (usage spikes from managers) and "persuasive stories" (re-tagged support tickets), which BK-0007 warns can look like progress while failing to test the critical assumption. The Commercial Cleanroom tests pricing and sales tactics, but not whether the product actually solves the claims problem.

The **Claim File Review** is the only option that provides a "load-bearing diagnosis" (BK-0001-card-001) of the actual challenge. By inspecting whether suggestions are accepted, rewritten, or "impossible to explain," you move from activity metrics to behavioral validation. This will reveal if the product is a genuine workflow accelerator or merely a tool that managers use for oversight while adjusters revert to manual notes.

### The Strongest Reason Against This Recommendation
The Claim File Review is a qualitative, small-sample exercise that provides no immediate "hard" financial data to the board. In a high-pressure twelve-day window, the CEO may view this as "endless analysis" (BK-0001 misuse risk) that fails to provide the quantitative certainty of a "Cleanroom" or the perceived velocity of a "Usage Sprint."

### Observable Evidence That Would Change My Mind
I would change this recommendation to the **Commercial Cleanroom** if you discovered that the primary strategic uncertainty was not *product utility* (do adjusters find it useful?), but rather *monetization viability* (will buyers pay for it without bundles/roadmap promises?). If the product is already known to be functionally sound but the pricing model is the only suspected failure point, the Cleanroom becomes the priority.

================  OUT-12  ================

---
anonymous_label: OUT-12
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: 4ebebd81cc53a483833c6f2e53454256e0b42f26825fc6390dda6577d8c221aa
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-12

**Recommendation:** Run the Claim File Review.

**Why:** The current "success" is an illusion created by lagging indicators (renewals driven by temporary pricing) and misleading usage metrics (managers rerunning samples rather than adjusters using the tool in live production). You have a critical "black box" problem: you know adjusters are abandoning the tool (especially in health-liability) and that managers are using it for enablement rather than operations, but you don't know *why* the suggestions are being overridden or deemed unexplainable. The Claim File Review is the only option that provides qualitative, ground-truth evidence of whether DraftPath actually solves a problem or is simply being "bought" by executives and ignored by users.

**Strongest Reason Against:** This is the slowest, most manual method of validation. Unlike the Usage Quality Sprint (which uses automated analytics) or the Commercial Cleanroom (which tests price elasticity), a file review requires human labor and time. By the time you have a statistically significant sample of reviewed files, you may have already missed the window to pivot the product before the next major churn cycle.

**Observable Evidence to Change My Mind:** If the "wrong recommendation" tickets in the training channel spike significantly in volume and specificity (e.g., a clear pattern of "the tool consistently fails at X step"), the Usage Quality Sprint becomes more valuable because the problem has shifted from "hidden abandonment" to "vocal dissatisfaction," which is easier to track via event logs and tags.

================  OUT-13  ================

---
anonymous_label: OUT-13
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: 4fe0b2c82ffcec054b186c380d6f7b2e398cd50da1db8dfc9f5bed751870d055
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-13

I recommend the **Claim File Review**.

### The Recommendation: Claim File Review
You are currently facing a "false positive" crisis. Your commercial metrics (bookings/renewals) are being inflated by temporary pricing and sales narratives, while your usage metrics are skewed by managers performing audits rather than adjusters performing work.

The Claim File Review is the only option that penetrates the "entangled" evidence to find the ground truth: **Does DraftPath actually solve a problem for the end-user, or is it merely a management reporting tool?**

By analyzing whether suggestions were accepted, overridden, or "impossible to explain," you will determine if the product has a fundamental utility gap (the health-liability issue) or an enablement gap. This allows you to enter the next budget cycle with a factual basis for whether to pivot, polish, or persevere, rather than guessing based on lagged churn data or manipulated sales cycles.

### The Strongest Reason Against It
**It is the slowest path to a "commercial" answer.** Unlike the Commercial Cleanroom, which tests willingness to pay, or the Usage Quality Sprint, which tracks behavioral trends in real-time, a file review is manual, qualitative, and small-sample. It does not provide the board with a "revenue forecast" or a "growth multiplier"; it provides a product diagnostic. In a high-pressure budget window, the CEO may view this as "academic" compared to the immediate revenue signals of a Cleanroom.

### Evidence That Would Change My Mind
I would switch my recommendation to the **Commercial Cleanroom** if you discover that the "impossible to explain" feedback in health-liability is a fringe edge case (affecting <5% of total volume) and the primary driver of current growth is purely price-sensitivity. If the product is "good enough" and the only real risk is that Sales is over-promising a roadmap to close deals, you no longer have a product problem—you have a pricing and positioning problem. In that case, validating the price floor is more urgent than auditing the claim files.

================  OUT-14  ================

---
anonymous_label: OUT-14
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: 532714c3fa08978a93d926cfc0bc02659bf42400f63c22461d566dc9778ebcf7
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-14

**Recommendation:** Run the **Claim File Review**.

**Why:** Your current success is a "mirage" created by lagging indicators and sales incentives. The expansion bookings are driven by temporary pricing bundles (financial incentive) and roadmap promises (future hope), not current product value. The usage data is misleading: high frequency is driven by managers performing audits, while front-line adjusters—the actual users—are abandoning the tool. Most critically, in the health-liability segment, there is a fundamental "explainability" gap that prevents the product from being used in a regulated environment.

The Usage Quality Sprint tracks *behavior* (which you already know is superficial), and the Commercial Cleanroom tracks *willingness to pay* (which will likely drop, but won't tell you how to fix the product). Only the Claim File Review provides the "ground truth" by auditing the actual output of the software against professional judgment. This will determine if DraftPath is actually solving a problem or if it is simply a "manager’s toy" that adjusters find burdensome.

**The strongest reason against it:** This is the slowest and most labor-intensive of the three validation options. It requires manual qualitative analysis of files rather than automated dashboards or sales reports, meaning you will have a smaller sample size and less "statistically significant" data to present to the board in twelve days compared to the Usage Quality Sprint.

**Observable evidence that would change my mind:** If you discover that the "abandonment" by front-line adjusters is purely a training/UI friction issue (e.g., they love the suggestions but hate the clicking) rather than a quality/trust issue (e.g., the suggestions are wrong or unexplainable), I would pivot to the **Usage Quality Sprint**. If the output is fundamentally sound but the delivery is clunky, you need a behavioral optimization loop, not a deep-dive file audit.

================  OUT-15  ================

---
anonymous_label: OUT-15
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: 5a018f3ddbcbc1ddba6859fbd2b13fef02c902ffa0318b69575cbb2c1e2fd2f2
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-15

I recommend that you commit to the **Claim File Review**.

### Reasoning
Your current situation is a classic "false positive" loop. You have strong lagging indicators (bookings, renewals) that are being driven by sales incentives (bundle pricing) and roadmap promises rather than realized product value.

The most dangerous signal in your data is the **adjuster behavior**: high initial adoption followed by a collapse back to manual notes, combined with an inability to explain the "why" in regulated segments. This suggests that DraftPath is currently a "manager’s toy"—useful for oversight and enablement demos, but failing the "utility test" for the actual practitioner.

Here is why the other options are insufficient or premature:
*   **Scaling Broadly:** This is a high-risk gamble. If the product lacks fundamental utility for adjusters, you are scaling a "leaky bucket" that will lead to massive churn once the bundle-price honeymoon ends.
*   **Usage Quality Sprint:** This measures *that* people aren't using the tool, but it doesn't tell you *why*. You already know the return rate is low; more dashboards won't fix a fundamental gap in explainability or trust.
*   **Commercial Cleanroom:** This tests the *sales pitch*, not the *product*. While it would prove that the bundle pricing is driving the bookings, it doesn't provide a path to fixing the product. It tells you that you have a revenue problem, but not how to build a value proposition.
*   **Narrowing to Health-Liability:** This is an overreaction. You have evidence of failure there, but you don't yet know if the failure is due to a lack of "explainability" (a solvable product gap) or a fundamental incompatibility with the segment.

The **Claim File Review** is the only option that attacks the "truth" of the value proposition. By auditing the actual claim files, you move from *proxy metrics* (clicks and bookings) to *outcome metrics* (accepted vs. rewritten plans). This will tell you if the AI is actually "right" but poorly presented, or fundamentally wrong.

### The Tradeoff
By choosing the Claim File Review, you are **displacing the Commercial Cleanroom**.

**What you give up:** You sacrifice the ability to definitively prove to the board exactly how much of your Q3 growth was "artificial" (driven by pricing) versus "organic." You will enter next year with a degree of uncertainty regarding your baseline expansion rate because you are not isolating the pricing variable. You are prioritizing **Product-Market Fit** over **Revenue Attribution**.

### The Strongest Reason Against This Recommendation
The Claim File Review is slow and qualitative. It provides a "snapshot" of a small sample size, which may be dismissed by the executive team or board as anecdotal compared to the "hard" 16% growth in bookings. There is a risk that while you are meticulously reviewing files, the sales team continues to sell a vision of DraftPath that the product cannot deliver, widening the gap between expectation and reality.

### Observable Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discover that the "regional carriers" who are removing DraftPath from their contracts are your highest-value, most sophisticated users.

If the "power users" (those who actually know how to use the tool) are the ones churning, while the "low-sophistication" users (who just like the bundle price) are renewing, it indicates that DraftPath is not just "unexplained," but fundamentally non-viable for professional use. In that case, the problem isn't a product tweak—it's a commercial delusion that needs to be corrected immediately via the Cleanroom.

================  OUT-16  ================

---
anonymous_label: OUT-16
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: 60a2366174d35bb731889d9ed8dd7c1bc2d509c166deec8b96e1334dec6f7568
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-16

I recommend that you commit to the **Claim File Review**.

### Reasoning and Trade-offs
Your current situation is a "false positive" trap. The executive team sees rising expansion bookings and usage percentages, but the underlying data suggests these are lagging indicators driven by sales incentives (bundle pricing) and administrative behavior (ops managers running samples), rather than core product-market fit for the end-user.

The most dangerous signal is the "abandonment" in the health-liability segment and the adjusters falling back to manual notes. In B2B workflow software, **usage $\neq$ value**. High usage by managers for enablement meetings is "performance art"; it doesn't prove the tool solves a pain point for the person actually doing the work.

Here is why the other options are insufficient:
*   **Scaling Broadly:** This is premature. You have evidence of "silent churn" (the regional carriers) and a lack of explainability in regulated segments. Scaling now would likely accelerate churn once the bundle-pricing honeymoon ends.
*   **Usage Quality Sprint:** This measures *behavior*, not *utility*. You already know the return rate is low for adjusters; knowing exactly how low it is via a dashboard doesn't tell you *why* they are abandoning the tool or how to fix it.
*   **Commercial Cleanroom:** This tests *willingness to pay*, but you have a product utility problem, not a pricing problem. If the adjusters aren't using it because they can't explain the output to reviewers, no amount of pricing strategy will save the renewal.
*   **Narrowing to Health-Liability:** This is a premature pivot. You know it's failing there, but you don't yet know if it's failing everywhere or just in highly regulated environments.

The **Claim File Review** is the only option that provides "ground truth." By auditing the actual claim files, you move from *proxy metrics* (clicks/bookings) to *outcome metrics* (accepted vs. overridden suggestions). This will tell you if DraftPath is actually providing a correct "next action" or if it is simply generating noise that adjusters are too tired to correct in a support ticket.

### The strongest reason against this recommendation
The Claim File Review is slow, manual, and "unsexy" compared to the growth narrative currently fueling the executive team's confidence. By choosing this, you are effectively telling the CEO and the Board that the "surprisingly strong quarter" may be an illusion. You risk appearing as a bottleneck to growth or "too academic" at a moment when the company feels it has found its stride. You are sacrificing the momentum of a "win" to investigate a potential failure.

### Observable evidence that would change my mind
I would pivot from the Claim File Review to **Scaling Broadly** if you can produce evidence that the "manual notes" fallback is actually a result of **UI friction** (e.g., it takes too many clicks to accept a plan) rather than **trust/utility friction** (e.g., the plan is wrong or unexplainable).

If a quick audit of the "enablement" meetings reveals that adjusters are actually saying, *"I love this, I just don't know how to move the data into my final report,"* then you have a distribution problem, not a value problem. In that specific case, the risk of scaling is lower because the core utility is already proven. However, based on the current reports of "impossible to explain" actions in regulated segments, this is unlikely.

================  OUT-17  ================

---
anonymous_label: OUT-17
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: 612fc5a7efb9a59ae07a02091747c36e4e83db60390d2b40d97c7e47f3353f89
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-17

**Recommendation:** Run the Claim File Review.

**Why:** Your current success is an illusion created by "entangled" evidence. You have a classic gap between *commercial signals* (expansion bookings driven by bundle pricing and sales pitches) and *product value* (adjusters abandoning the tool or using it only under managerial surveillance). The Usage Quality Sprint measures *how much* people use the tool, but not *why* or if it is actually solving the problem. The Commercial Cleanroom measures *willingness to pay*, but not *product-market fit*.

The Claim File Review is the only option that addresses the core risk: that DraftPath provides "correct" recommendations (fewer wrong-recommendation tickets) that are nonetheless unusable in a professional workflow (impossible to explain to reviewers). By analyzing the actual delta between a DraftPath suggestion and the final action taken on a file, you determine if the product is providing genuine utility or merely acting as a template that adjusters are manually correcting. This evidence is critical before scaling or narrowing the segment, as it reveals whether the problem is a lack of "enablement" (training) or a fundamental failure in the product's logic.

**The strongest reason against it:** It is slow and labor-intensive compared to the Usage Quality Sprint. By the time you manually review claim files and interview adjusters, the board's twelve-day window will have closed, and you may lack a "hard" quantitative metric (like a return-rate dashboard) to justify the budget to an executive team currently intoxicated by expansion bookings.

**Observable evidence that would change my mind:** If the "training channel" support tickets revealed a specific, easily fixable UI/UX friction point—rather than a conceptual failure to explain the "why" behind a recommendation—I would switch to the Usage Quality Sprint. If the problem is purely "how to use the button," quantitative tracking suffices; if the problem is "the output is indefensible to a regulator," only the Claim File Review will find it.

================  OUT-18  ================

---
anonymous_label: OUT-18
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: 63b5453a812d86e4b195d42bdf756d80517f3ecb050141f048143e5fab863ee0
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-18

I recommend that you commit to the **Claim File Review**.

### The Reasoning
You are currently facing a "false positive" signal. Your financial metrics (expansion bookings) and surface-level usage metrics (39% increase) are being driven by incentives (bundle pricing), managerial vanity/reporting (ops managers rerunning samples), and sales narratives (roadmap pitches).

The core risk is that DraftPath provides **perceived value** to the buyer (the person signing the check) but lacks **functional utility** for the user (the adjuster). In B2B workflow software, this gap is a leading indicator of catastrophic churn.

Here is why the other options are insufficient:
*   **Scale Broadly:** This is reckless. You have evidence of "novelty spikes" (heavy use for two days, then abandonment) and a failure in the health-liability segment. Scaling a leaky bucket only accelerates churn.
*   **Usage Quality Sprint:** This measures *how often* people click, not *why* they stop. High return rates could simply be managers forcing adoption. It doesn't solve the "explainability" crisis in regulated segments.
*   **Commercial Cleanroom:** This tests price elasticity and sales messaging, but it doesn't tell you if the product actually works. If the product is fundamentally flawed for the adjuster, a "cleanroom" only proves that you can't sell a bad product without a discount.
*   **Narrow to Health-Liability:** This is a premature pivot based on one failure point. You don't yet know if the issue is the product’s logic or simply a lack of "audit trail" features for regulators.

The **Claim File Review** is the only option that provides "ground truth." By auditing actual files, you move from *proxy metrics* (clicks and bookings) to *outcome metrics* (acceptance vs. override). This will tell you if DraftPath is a productivity tool or a "theatre" tool.

### The Trade-off
By choosing the Claim File Review, you are **displacing the Commercial Cleanroom**.

**What you give up:** You sacrifice the ability to know exactly how much "pricing power" DraftPath has in a vacuum. You will enter the next fiscal year without knowing if you can maintain expansion margins without bundle discounts. You are choosing *product-market fit* over *price-market fit*.

### The Strongest Reason Against This Recommendation
The Claim File Review is slow, manual, and qualitative. It provides a snapshot of a small sample size rather than the aggregate data of a "Sprint." If the board is purely focused on the 12-day budget window, they may view a qualitative review as "too academic" compared to the hard financial data of a Cleanroom or the scale-up potential of broad deployment. It does not provide an immediate "revenue" answer, only a "risk" answer.

### Evidence That Would Change My Mind
I would switch my recommendation to **Narrow the company plan around regulated health-liability workflows** if the Claim File Review reveals that the "impossible to explain" feedback is not a feature gap, but a fundamental limitation of your AI/logic engine.

If the audit shows that adjusters *want* to use the tool but are legally prohibited from doing so because of the "black box" nature of the suggestions, you no longer have a general workflow problem—you have a regulatory compliance problem. In that case, the only path to survival is to rebuild the product specifically for the constraints of regulated health-liability.

================  OUT-19  ================

---
anonymous_label: OUT-19
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: 66d677c9c71626232a6010e9c8b3d22f2fc816b1ef35c04e5da2435d5c529001
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-19

I recommend the **Claim File Review**.

### The Recommendation
You should commit to the Claim File Review. Your current "success" is an illusion created by financial incentives (bundle pricing) and managerial vanity (ops managers using the tool for enablement rather than production). You have a critical "black box" problem: you know *that* users are abandoning the tool or using it incorrectly, but you don’t know *why*—whether it is a failure of the AI's logic, a failure of the UI to provide an audit trail (the "explainability" gap in health-liability), or a failure of the user's trust.

The Claim File Review is the only option that audits the **actual work product**. By analyzing whether suggestions were accepted, overridden, or rewritten, you move from "proxy metrics" (usage percentages) to "value metrics" (accuracy and utility). This provides the ground truth necessary to decide if DraftPath is a scalable product or a sophisticated demo that closes deals but fails to deliver value.

### The Strongest Reason Against It
The Claim File Review is slow, manual, and qualitatively "noisy" compared to the other options. While the Commercial Cleanroom provides immediate financial validation and the Usage Quality Sprint provides high-velocity data, the File Review requires tedious human auditing. By choosing this, you sacrifice the ability to quantitatively prove to the Board—via a controlled experiment—exactly how much of your expansion revenue is driven by product value versus sales discounting.

### The Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discovered that your current pipeline of "intent" for next year is almost entirely dependent on the bundle-price incentive. If a cursory audit of the sales pipeline reveals that 80%+ of expansion leads are tied to the expiring discount, you no longer have a product-market fit problem; you have a pricing and packaging crisis. In that scenario, validating the technical utility of the tool is secondary to discovering if anyone is actually willing to pay full price for it.

================  OUT-20  ================

---
anonymous_label: OUT-20
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: 6b1128d40f5da40f692cefe4226d2fcce0601cd5f522f05a9c2abc68468a76a9
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-20

I recommend that you commit to the **Claim File Review**.

**Why?**
Your current success is an "entangled" signal. The financial growth is heavily skewed by temporary pricing bundles (incentivizing timing, not value), and the usage growth is driven by managers performing audits rather than adjusters performing work. You have a "false positive" situation: the executive team believes you are aligned around the right buyer, but the evidence suggests a gap between *buyer* perception (who likes the roadmap pitch) and *user* utility (adjusters who abandon the tool or cannot justify its output to reviewers).

The Usage Quality Sprint measures *behavior* (return rates), but not *efficacy*. The Commercial Cleanroom measures *willingness to pay*, but cannot tell you how to fix the product. Only the Claim File Review addresses the core risk: whether DraftPath actually solves a problem or is simply being "tolerated" until procurement windows close. By analyzing the gap between proposed actions and accepted/rewritten actions, you determine if the product is a functional tool or a superficial feature.

**The strongest reason against this recommendation:**
It is the slowest path to "certainty" for a board meeting happening in twelve days. Unlike the Usage Quality Sprint (which provides a dashboard) or the Cleanroom (which tests pricing), the File Review is qualitative and manual. It does not provide a "hard number" to justify the budget; it provides a diagnosis of failure or success. If the board is primarily concerned with short-term revenue predictability rather than long-term product viability, they may view this as too academic.

**Observable evidence that would change my mind:**
If the "regional carriers" who intend to remove DraftPath provide specific, documented feedback that their abandonment is purely due to a lack of training/enablement (rather than the inability to explain actions to reviewers or poor recommendation quality), I would switch to the **Usage Quality Sprint**. In that case, the problem is a "delivery" issue rather than a "value" issue.

================  OUT-21  ================

---
anonymous_label: OUT-21
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: 6bb0feb697c659a5e21a2dff262cede7d75a4100a4479a76fdf448b5fcefeadb
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-21

I recommend that you commit to the **Claim File Review**.

### Reasoning
You are currently facing a "false positive" signal. Your financial metrics (expansion bookings) are being driven by sales incentives (bundle pricing) and roadmap promises, not necessarily by product value. Your usage metrics are being inflated by managers (non-users) and a "novelty spike" among adjusters who eventually revert to manual habits.

The most dangerous signal in your data is the **explainability gap** in the health-liability segment. In a regulated industry, a tool that provides a "correct" answer that cannot be defended to a reviewer is functionally useless.

The other options fail for the following reasons:
*   **Scaling Broadly:** This is premature. You have evidence of "silent churn" (the regional carriers) and a lack of habitual usage. Scaling now would likely increase the volume of "impossible to explain" errors and accelerate churn once bundle pricing expires.
*   **Usage Quality Sprint:** This measures *what* is happening (quantitative) but not *why* it is happening (qualitative). You already know the "what": adjusters stop using it after two days. More dashboards won't tell you why they are reverting to manual notes.
*   **Commercial Cleanroom:** This is a sales experiment, not a product one. While it would prove whether the roadmap pitch is driving renewals, it doesn't fix the underlying product deficiency. You would be testing if people are willing to buy a broken tool, rather than fixing the tool so people want to buy it.
*   **Narrowing to Health-Liability:** This is a premature pivot. You have evidence of struggle in this segment, but you don't yet know if the issue is a fundamental product limitation or a solvable UX/documentation problem.

The **Claim File Review** is the only option that attacks the "ground truth." By seeing exactly where suggestions are overridden or rewritten, you move from guessing why usage drops to knowing exactly which "next actions" are failing. This provides the evidence needed to decide whether to pivot the product or double down on a specific segment.

### The Tradeoff
By choosing the Claim File Review, you are **displacing the Commercial Cleanroom**.

**What you give up:** You sacrifice the ability to definitively prove—via a controlled experiment—how much of your current revenue growth is "artificial" (driven by bundle pricing) versus "organic" (driven by product value). You are choosing to solve the product-market fit problem before solving the pricing-model problem.

### The Strongest Reason Against This Recommendation
The Claim File Review is slow and manual. It provides a "snapshot" of a small sample size, whereas the Board typically prefers the perceived certainty of large-scale quantitative data (like the Usage Quality Sprint). There is a risk that the Board views this as "over-analyzing" while the sales momentum is high, potentially viewing your caution as a lack of aggression.

### Evidence That Would Change My Mind
I would change this recommendation to the **Commercial Cleanroom** if you discovered that the "silent churn" from regional carriers was not due to product utility, but specifically due to a pricing misalignment (e.g., they love the tool but find the bundle price prohibitive). If the problem is *commercial* rather than *functional*, fixing the product won't save the renewals.

================  OUT-22  ================

---
anonymous_label: OUT-22
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: 6bd705c7b5d45561b8798fc51db4ba4f7b017b853421362255cf379667d93f38
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-22

**Recommendation:** Run the Claim File Review.

**Why:** Your current success metrics are "entangled" and likely illusory. The expansion bookings are skewed by temporary pricing bundles, and the usage spike is driven by managers auditing closed files rather than adjusters managing active claims. Most critically, the "invisible churn" from regional carriers and the abandonment in the health-liability segment suggest a fundamental gap between the tool's output and the user's ability to defend that output to reviewers. You cannot scale or optimize (Usage Quality Sprint) a product if you do not know whether the core output is actually being accepted or rewritten. The Claim File Review provides the only ground-truth data on whether DraftPath is providing genuine value or merely appearing useful in a demo.

**Strongest Reason Against:** It is the slowest and most manual of the three proposed tests. Unlike the Usage Quality Sprint (automated tracking) or the Commercial Cleanroom (sales gating), this requires human labor to audit files and interview adjusters, which may feel too slow given the twelve-day budget window.

**Evidence that would change my mind:** If the "Commercial Cleanroom" results were to show that buyers are still enthusiastically signing expansion agreements at full price without the roadmap pitch or bundle discounts. That would prove the perceived value is high enough to sustain the business while you figure out the usage gaps in the background.

================  OUT-23  ================

---
anonymous_label: OUT-23
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: 6bec08f247873bd2dc4c147e807b4148796c9fa7ffa66632278145bac2508cbf
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-23

**Recommendation: Run the Claim File Review.**

The current growth metrics are contaminated. Expansion revenue is tied to temporary pricing incentives rather than product value, and "enthusiastic" feedback was solicited by sales teams promising future roadmap updates. Furthermore, usage data is skewed by managers performing retrospective audits rather than adjusters using the tool in live production. The Claim File Review is the only intervention that bypasses these biases by examining the actual work product (the claim file) rather than reported sentiment or superficial activity logs. It will reveal if the tool is solving a core problem or if it is being bypassed by adjusters once the initial novelty wears off.

**Strongest reason against this recommendation:**
This approach is slow and labor-intensive compared to the Usage Quality Sprint. It provides a snapshot of quality rather than a real-time trend line and does not immediately test the commercial elasticity of the product without the bundle pricing.

**Observable evidence that would change my mind:**
If the Commercial Cleanroom were to show that a significant percentage of accounts still sign expansion agreements at full price without the roadmap pitch, it would prove that a hidden value proposition exists despite the poor adjuster adoption. In that case, I would switch to the Commercial Cleanroom to identify which specific buyer persona is driving the value.

================  OUT-24  ================

---
anonymous_label: OUT-24
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: 713641ba188f49cd68278b2e1b9e969af9017ed427978ce8299838c56c154bc5
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-24

I recommend that you commit to the **Claim File Review**.

### Rationale
The current evidence for DraftPath’s success is heavily contaminated by "performance-aware attribution" (BK-0048). The executive team’s praise for the product team's "discipline" and "alignment" follows a strong quarter, but that strength is likely driven by temporary bundle pricing and sales pitches rather than product value.

The core uncertainty is whether DraftPath solves a real problem for the user or if it is merely "activity" that looks like progress (BK-0007). Usage rose 39%, but the data reveals this is driven by managers (not adjusters) and initial novelty. The most critical failure point is the "explainability" gap in regulated health-liability, where users abandon the tool because they cannot justify its output to reviewers.

The **Claim File Review** is the only proposal that provides a "load-bearing diagnosis" (BK-0001) of the actual challenge. By inspecting whether suggestions were accepted, overridden, or impossible to explain, you move past "broad activity metrics" and determine if the product is actually functioning as a workflow solution or merely a decorative feature.

*   **Why not the Usage Quality Sprint?** This focuses on "enablement" and "return rates," which are activity metrics that can fail to disconfirm the favored story (BK-0007).
*   **Why not the Commercial Cleanroom?** While it tests pricing sensitivity, it does not tell you *why* the product is failing in specific segments or how to fix the core value proposition.
*   **Why not Scale Broadly?** Scaling based on contaminated data risks baking in a flawed strategy.

### The Strongest Reason Against This Recommendation
The Claim File Review is qualitative and slow. It provides a deep understanding of *why* the product fails, but it does not provide the immediate, quantitative "proof" of revenue protection that a board often demands during budget locks. It risks being dismissed as "endless analysis" (BK-0001) rather than a decisive strategic step.

### Evidence That Would Change My Mind
I would change this recommendation if the **Commercial Cleanroom** results (if run) showed that expansion bookings remained stable even without bundle pricing and roadmap pitches. If the financial lift were decoupled from sales incentives, it would suggest the value proposition is strong enough to survive the current "explainability" issues, making broad scaling a lower-risk bet.

================  OUT-25  ================

---
anonymous_label: OUT-25
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: 7acbd1b4fd9f7ba47f842ee631f12ace2d919384ebfd828a6073dfaa598f9506
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-25

**Recommendation:** Run the Claim File Review.

**Why:** Your current success is an illusion created by "entangled" data. The expansion bookings are driven by temporary pricing (financial incentive), not necessarily product value. The usage spikes are coming from managers (supervisory use) rather than the primary users—front-line adjusters—who are abandoning the tool after two days. Most critically, in the health-liability segment, there is a fundamental "Jobs to be Done" failure: the tool provides an answer but not the *justification* required for regulatory compliance.

The Usage Quality Sprint measures *if* they use it, and the Commercial Cleanroom measures *if* they will pay for it, but neither explains *why* the adjusters are reverting to manual notes. The Claim File Review is the only option that provides a qualitative audit of the actual output (accepted vs. overridden). This allows you to determine if DraftPath is solving a core workflow problem or simply providing a "feel-good" demo that closes deals but fails in production.

**Strongest Reason Against:** This is the slowest and most labor-intensive of the validation options. While the board locks the budget in twelve days, a manual file review may not yield statistically significant results before the deadline, potentially leaving you to make a budget commitment based on an incomplete sample size.

**Evidence that would change my mind:** If the "Commercial Cleanroom" results were to show that buyers are renewing and expanding *specifically* because of the DraftPath roadmap pitch, despite the current usage flaws. If the market is buying a "vision" of future capability rather than the current utility, the priority would shift from product-market fit (File Review) to commercial validation (Cleanroom).

================  OUT-26  ================

---
anonymous_label: OUT-26
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: 7b78df2fa5f558fb2d63d9fb75cd8b4feb6aec7f62058be79c3265a917dca650
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-26

**Recommendation:** Run the Claim File Review.

**Why:** The company is facing a "false positive" crisis where financial metrics (expansion bookings) and surface-level analytics (usage spikes) are masking fundamental product failure. The "strong quarter" is likely an artifact of aggressive sales bundling and managers using the tool for auditing rather than adjusters using it for production. Because front-line adjusters are abandoning the tool and health-liability users cannot justify its outputs to reviewers, you have a "black box" problem. You cannot scale or refine the product until you understand *why* suggestions are being overridden or ignored at the file level. The Claim File Review is the only option that provides the qualitative "ground truth" necessary to determine if DraftPath provides actual utility or is merely a sales catalyst.

**Strongest Reason Against:** This is the slowest and most labor-intensive of the three validation tests. Unlike the Usage Quality Sprint (which relies on automated event tracking) or the Commercial Cleanroom (which relies on contract outcomes), a file review requires manual inspection and interviews, delaying the "answer" as the board budget deadline approaches.

**Observable Evidence to Change My Mind:** If the "Commercial Cleanroom" results were to show that renewal rates and expansion intent remain identical even without bundle pricing or roadmap pitches, it would prove the product has intrinsic market value regardless of the current usability gaps. In that case, I would pivot to recommending the Usage Quality Sprint to optimize a product that is already selling itself.

================  OUT-27  ================

---
anonymous_label: OUT-27
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: 7db47b9f7f8a8815df16e7d28cd8a2458edb54cbbd3795102599d50cfd9bf0ee
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-27

I recommend that you commit to the **Claim File Review**.

### Rationale
The current evidence for DraftPath’s success is heavily contaminated by "performance-aware attribution" (BK-0048). The executive team’s praise of the product team's "discipline" and "alignment" follows a strong quarter, but the financial wins are entangled with temporary bundle pricing and sales-led roadmap pitches rather than proven product value.

Furthermore, your usage metrics are "broad activity metrics" that may be masking a lack of actual progress (BK-0007). High usage by managers rerunning samples and initial spikes from adjusters do not validate the core strategic assumption: that DraftPath solves a load-bearing problem for the end-user (BK-0001). The most critical uncertainty is whether the tool provides a usable, explainable output for the adjuster—particularly in regulated segments where it is currently being abandoned.

The **Claim File Review** is the only proposal that tests the "load-bearing diagnosis" of whether the tool actually works in the workflow. Unlike the Usage Quality Sprint (which tracks *if* they use it) or the Commercial Cleanroom (which tracks *if* they buy it), the File Review reveals *why* it is being overridden or abandoned. This provides the independent causal evidence needed to decide if you should scale, pivot, or narrow your focus.

### The Strongest Reason Against This Recommendation
The Claim File Review is a qualitative, small-sample exercise that provides "lagging" evidence of utility. It does not offer the immediate, statistically significant financial validation that the Board likely desires twelve days before budget lock. By choosing this over the Commercial Cleanroom, you sacrifice the ability to prove that DraftPath can drive expansion bookings without the "crutch" of bundle pricing.

### Evidence That Would Change My Mind
I would change this recommendation to the **Commercial Cleanroom** if you could provide evidence that the primary risk to next year's budget is not *product utility* (whether it works), but *pricing elasticity* (whether customers will pay for it at full price). If the "load-bearing diagnosis" is already solved and the only remaining uncertainty is the commercial model, then validating the price point becomes more urgent than validating the workflow.

================  OUT-28  ================

---
anonymous_label: OUT-28
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: 900b7f08cdf446fb5c9dbdf52a6e94d793356cf8a0a55c1049528b48d2c1b984
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-28

**Recommendation:** Run the **Claim File Review**.

**Why:**
Northstar Claims is currently experiencing a "Halo Effect" where positive financial lagging indicators (expansion bookings, early renewals) are being incorrectly attributed to the value of DraftPath. The evidence suggests a dangerous gap between *perceived* value (buyer enthusiasm, manager usage) and *actual* utility (adjuster abandonment, inability to explain actions to reviewers).

The "Usage Quality Sprint" tracks *that* people use the tool, but not *why* they stop or how it fails. The "Commercial Cleanroom" tests pricing elasticity and sales narratives, but not product-market fit. Only the Claim File Review provides a high-fidelity look at the "Job to be Done"—specifically whether the tool's output is functionally useful or merely a superficial aid for managers. Given that adjusters in the health-liability segment are abandoning the tool due to a lack of explainability, you have a fundamental product failure that no amount of "enablement" or pricing strategy can fix. You must determine if DraftPath is providing actual value or if you are simply selling a roadmap promise that the product cannot fulfill.

**The strongest reason against it:**
It is the slowest and most labor-intensive of the validation options. Unlike a dashboard (Sprint) or a sales test (Cleanroom), it requires manual qualitative analysis of files and interviews. In the twelve-day window before the board locks the budget, this approach provides a "small sample" snapshot rather than a statistically significant data set, risking a decision based on anecdotal evidence from a few accounts.

**Observable evidence that would change my mind:**
If the "Commercial Cleanroom" were to reveal that renewal objections are driven exclusively by price sensitivity rather than product utility, or if the "Usage Quality Sprint" showed that return rates among front-line adjusters were actually stable and high across all segments (contradicting the current reports of abandonment), I would pivot to a commercial validation strategy.

================  OUT-29  ================

---
anonymous_label: OUT-29
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: 9be49fe7e8f2d4d8e34c7029850d437314ae8946619da68cce3726fec4b78dc1
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-29

I recommend that you commit to the **Claim File Review**.

### Rationale
The current evidence suggests your "surprisingly strong quarter" is an illusion created by three distinct types of noise identified in the provided artifacts:

1.  **Performance-Aware Attribution (BK-0048-card-001):** The executive team's sudden praise for the product team’s "discipline" and "alignment" occurred *after* the strong financial outcomes. This is a classic case of contaminated trait narratives; the leadership is attributing success to "culture" and "focus" because the numbers are up, not necessarily because those traits caused the numbers.
2.  **False Progress Metrics (BK-0007-card-001):** Your usage growth (39%) is a "broad activity metric" that masks failure. The high frequency comes from managers (not the primary users) and initial novelty spikes, while front-line adjusters abandon the tool. This "looks like progress" but fails to validate the core strategic assumption: that DraftPath provides sustainable value to the adjuster.
3.  **Confounded Revenue (BK-0001-card-001):** The expansion bookings are tied to temporary bundle pricing and roadmap promises, not a validated diagnosis of a solved problem.

The **Claim File Review** is the only proposal that seeks "evidence that can make a strategic assumption wrong" (BK-0007). By inspecting the actual output (accepted vs. rewritten vs. impossible to explain), you move from "persuasive stories" and "dashboards" to a load-bearing diagnosis of whether the product actually works. The Usage Quality Sprint is merely more dashboarding, and the Commercial Cleanroom tests sales tactics rather than product utility.

### The Strongest Reason Against
The Claim File Review is slow and qualitative. It will not provide the "clean" statistical significance of a Cleanroom or the real-time tracking of a Sprint. Because it requires manual inspection of files, it may produce a small sample size that the executive team—currently riding a wave of optimism—might dismiss as "anecdotal" compared to the 16% expansion growth.

### Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discovered that the regional carriers removing DraftPath from their contracts were doing so specifically because of price-sensitivity or procurement policy, rather than a lack of product utility. If the "churn" is purely financial and not functional, the priority shifts from validating the product's value (Claim File Review) to validating the pricing model and sales pitch (Commercial Cleanroom).

================  OUT-30  ================

---
anonymous_label: OUT-30
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: a0f9d81709ad2f2b822ef631cce2eac229cdcbf1acc6db4164dfddd24f166761
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-30

I recommend the **Claim File Review**.

### Rationale
The current evidence for DraftPath's success is heavily contaminated. According to **BK-0048-card-001**, the executive team’s current praise of the product team as "focused" and "disciplined" is likely a result of performance-aware attribution—they are attributing the strong quarter to team traits because they already know the financial outcome.

Furthermore, the financial growth is confounded by "bundle pricing" (a price incentive) and roadmap pitches (a future promise), rather than the current value of the feature. The usage metrics are similarly misleading: high frequency is driven by managers (non-users) and initial curiosity, while front-line adjusters—the primary users—abandon the tool.

Per **BK-0007-card-001**, you need evidence that can "disconfirm the favored story." The Usage Quality Sprint and Commercial Cleanroom measure *activity* and *intent*, but they do not test the "load-bearing diagnosis" (**BK-0001-card-001**) of whether DraftPath actually solves the core problem for adjusters. The Claim File Review is the only option that provides independent causal evidence by auditing the actual work product (the claim files) to see if the software's output is being accepted, rewritten, or ignored.

### The Strongest Reason Against This Recommendation
The Claim File Review is a qualitative, small-sample audit that will not provide the "hard" statistical confidence or immediate revenue forecasting that the board likely desires twelve days before budget lock. It risks being dismissed by the executive team as "anecdotal" compared to the 16% expansion growth and 39% usage spike.

### Observable Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you could provide evidence that the "bundle pricing" was a negligible factor in renewals (e.g., if 80% of expansion dollars came from accounts that paid full price). If the financial lift was independent of the discount, the primary uncertainty would shift from "Does the product work?" to "Is the market willing to pay for it?", making the Cleanroom the higher-priority test.

================  OUT-31  ================

---
anonymous_label: OUT-31
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: a2e21014725fe545fcf73b612bbcbf2ac0c4895545faa0b5f1229466c0545c55
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-31

**Recommendation: Run the Claim File Review.**

**Why:**
Your current growth signals are "false positives" driven by financial engineering (bundle pricing) and sales narratives (roadmap promises), not product value. The 39% usage spike is an illusion; it is driven by managers performing audits, not adjusters performing work.

You are facing a critical "Value Gap": front-line users abandon the tool unless supervised, and health-liability users cannot justify its output to regulators. If you scale now, you are scaling a liability that will trigger massive churn once procurement windows open. The *Usage Quality Sprint* only measures *if* they use it (which you already know is superficial), and the *Commercial Cleanroom* measures *if* they will pay for it (which is irrelevant if the product doesn't actually work). The *Claim File Review* is the only option that identifies *why* it is being overridden or abandoned. It converts "enthusiastic comments" into hard data on accuracy and explainability, allowing you to fix the product before the renewal cliff hits.

**The strongest reason against it:**
It is the slowest and most labor-intensive of the three validation tests. While a dashboard (Sprint) or a sales experiment (Cleanroom) provides immediate quantitative data, the File Review requires manual effort from adjusters and reviewers. In a twelve-day window to lock the budget, this approach risks providing "anecdotal" qualitative data rather than a statistically significant "green light" for the board.

**Observable evidence that would change my mind:**
If you discover that the "manual overrides" in health-liability are not due to a failure of the AI’s logic, but are instead caused by a missing UI field for "Regulatory Justification." If the problem is a simple documentation gap rather than a core logic/trust failure, I would pivot to the **Usage Quality Sprint** to quickly validate if a simple UI fix restores the adjuster return rate.

================  OUT-32  ================

---
anonymous_label: OUT-32
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: a4d63129f53cd022667129fa13e8984e7045ea297b25fd6e9409b7b4c5898de2
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-32

I recommend that you commit to the **Claim File Review**.

### Reasoning and Tradeoffs

You are currently facing a "false positive" signal. Your financial metrics (expansion bookings) and vanity metrics (usage percentages) are being driven by incentives—bundle pricing for sales and "sample auditing" by managers—rather than core product value.

The most dangerous signal in your data is the behavior of front-line adjusters: they use the tool for 48 hours and then revert to manual notes. This suggests DraftPath is perceived as a "novelty" or a "compliance checkbox" rather than a utility. If you scale now, you are scaling a feature that adjusters find untrustworthy or cumbersome.

Here is why the other options are inferior in this specific window:
*   **Scaling Broadly:** This is high-risk. You have early warnings of churn from regional carriers and a fundamental "explainability" failure in the health-liability segment. Scaling a flawed workflow creates technical and reputational debt.
*   **Usage Quality Sprint:** This is "more of the same" quantitative data. You already know *that* they aren't returning; you don't know *why*. Tracking the decline in real-time doesn't fix the product.
*   **Commercial Cleanroom:** This is a sales experiment, not a product one. While it would prove if the bundle pricing is masking a lack of value, it doesn't tell you how to fix DraftPath. It tells you if the product is sellable, not if it is usable.
*   **Narrowing to Health-Liability:** This is a premature pivot. You have evidence that it's failing there, but you don't yet know if it's a universal failure of the logic or a specific regulatory hurdle.

**The Claim File Review is the only option that addresses the "Ground Truth."** By auditing actual files, you move past what users *say* in sales calls and what the *dashboard says* about clicks. You will see exactly where the "manual rewrite" happens. This allows you to determine if DraftPath is providing a 10% lift (worth scaling) or a 0% lift that requires 20% more effort to verify (a liability).

### The Modification
I recommend modifying the Claim File Review to include a **"Regulatory Gap Analysis."** This displaces the general "Claim File Review" by specifically requiring a subset of files from the health-liability segment to be reviewed alongside their internal compliance checklists.
*   **What you give up:** You sacrifice a broader, random sample of all account types to spend more time on the high-friction health-liability segment.

### The Strongest Reason Against This Recommendation
The Claim File Review is slow, qualitative, and "unscalable." While the board wants a budget for next year, this review provides anecdotal evidence rather than a clean spreadsheet of ROI. There is a risk that the CEO will find the results too "small-sample" to justify a major strategic shift, whereas the Commercial Cleanroom provides hard revenue numbers that executives typically prefer.

### The Evidence That Would Change My Mind
If the **regional carriers** who plan to remove DraftPath provide specific, documented feedback that their adjusters *love* the tool but the *procurement/legal* teams are blocking it due to pricing or contract terms, I would pivot to the **Commercial Cleanroom**.

If the friction is purely financial/contractual, you have a pricing problem. But if the friction is "the adjusters stopped using it after two days," you have a product problem—and only the Claim File Review can diagnose that.

================  OUT-33  ================

---
anonymous_label: OUT-33
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: a6bae10e98e108e06467de9b4dbb6c92223f231fe235e8c48d47a8b64fc6d90d
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-33

**Recommendation:** Run the **Claim File Review**.

**Why:** Your current growth signals are "entangled" and potentially illusory. Expansion bookings are skewed by temporary pricing bundles, and usage spikes are driven by managers auditing old files rather than adjusters managing active claims. Most critically, you have a "black box" problem: health-liability adjusters are abandoning the tool because they cannot explain its logic to reviewers. Before scaling or testing pricing (Commercial Cleanroom), you must determine if the product provides actual utility or if it is simply being "performed" for managers. The Claim File Review is the only option that provides ground-truth data on whether a recommendation was accepted, rewritten, or ignored, allowing you to distinguish between "usage" (clicks) and "value" (outcomes).

**Strongest Reason Against:** This is a manual, qualitative process that is slower and less scalable than the Usage Quality Sprint. It provides a snapshot of behavior rather than a real-time dashboard, meaning you risk making a budget decision based on a small sample size rather than aggregate behavioral data.

**Evidence that would change my mind:** If the "wrong recommendation" tickets in the training channel were found to be overwhelmingly caused by a lack of user onboarding (UI/UX friction) rather than a failure of the underlying logic (product utility), I would switch to the **Usage Quality Sprint** to optimize enablement and retention.

================  OUT-34  ================

---
anonymous_label: OUT-34
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: ab0b9deec1630fbaaba004a48e5d727828b29120f878ae7a9fc22788391f0d77
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-34

**Recommendation:** Run the Claim File Review.

**Why:** The current signals are "entangled" and misleading. Expansion bookings are inflated by temporary pricing bundles, usage spikes are driven by managers (not the end-users), and support ticket decreases are a result of miscategorization. You cannot determine if the product provides actual value or is simply being "sold" effectively by account teams. The Claim File Review is the only option that bypasses these noisy proxies to provide ground-truth evidence on whether DraftPath's output is actually useful, accurate, or explainable to the adjuster. This is a prerequisite for any scaling decision or strategic pivot.

**Strongest Reason Against:** It is the slowest and most manual of the three validation options. Unlike the Usage Quality Sprint (automated tracking) or the Commercial Cleanroom (sales process change), a file review requires human labor and subjective analysis, which may delay the "hard data" the board expects for budget locking.

**Evidence that would change my mind:** If you discovered that the "abandonment" in the health-liability segment was not due to a lack of explainability (the "why"), but rather a technical integration failure or a specific UI bug. In that case, I would switch the recommendation to the Usage Quality Sprint to pinpoint the exact friction point in the user journey.

================  OUT-35  ================

---
anonymous_label: OUT-35
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: b2b180bfddcd687ddfe1ffb97d237d631baf58447a9adb431f6ffc0c01265304
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-35

I recommend that you commit to the **Claim File Review**.

### The Reasoning
You are currently facing a "false positive" crisis. Your lagging indicators (expansion bookings, renewals) are being artificially inflated by sales incentives (bundle pricing) and roadmap promises. Your leading indicators (usage) are being skewed by "vanity usage" from managers who aren't actually using the tool for its intended purpose: accelerating claims resolution.

The core risk is that DraftPath is a "demo-ware" feature—it looks impressive to buyers and managers, but it fails the "last mile" of utility for the front-line adjuster. The evidence in the health-liability segment is a canary in the coal mine: if an adjuster cannot explain a recommendation to a reviewer, the software is a liability, not an asset.

The **Usage Quality Sprint** tracks *that* people are using it, but not *why* or if the output is correct. The **Commercial Cleanroom** tests pricing power, but you cannot price a product that isn't providing durable value. The **Claim File Review** is the only option that investigates the "truth" of the product: whether the AI's output actually matches the professional judgment of a claims expert. If you find that adjusters are manually rewriting 60% of the plans, no amount of "enablement" or "bundling" will prevent a churn wave in 12 months.

### Trade-offs and Sacrifices
By choosing the Claim File Review, you are sacrificing **immediate commercial certainty**. You are telling the CEO and Board that you cannot yet confirm if the recent revenue spike is organic or artificial. You are also giving up the "fast" quantitative data of the Usage Quality Sprint in favor of slower, qualitative manual audits. You are essentially choosing "Product Truth" over "Sales Momentum."

### The Strongest Reason Against This Recommendation
The Claim File Review is the slowest and most labor-intensive of the options. It requires manual effort from already-stressed adjusters and internal reviewers. In a high-pressure environment where the board is looking for "win" narratives to justify next year's budget, recommending a deep-dive audit that might reveal the product is failing its primary users can be perceived as "momentum killing" or overly academic. It risks alienating a Sales team that is currently hitting their numbers.

### Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discovered that the two regional carriers who plan to remove DraftPath are "outliers" (e.g., they have unique legacy tech stacks or atypical workflows) and that the "abandonment" in health-liability is due to a specific, easily fixable UI gap (like a missing "Reasoning" field) rather than a fundamental failure of the AI's logic. If the friction is purely *presentational* and not *functional*, you don't need a file review; you need to test if the market will pay for the fix.

================  OUT-36  ================

---
anonymous_label: OUT-36
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: c6cd077a5496eff2cc2ce80173bf9e93323edd1b3b9a158f33c121f2525f1f9d
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-36

**Recommendation:** Run the Claim File Review.

**Why:**
The current "strong quarter" is a classic example of the Halo Effect: executive leadership is attributing financial success to product-market fit (DraftPath) when the evidence suggests it is actually driven by pricing incentives (bundle discounts) and sales narratives (roadmap pitches).

The quantitative data is deceptive. Usage is up, but the behavior is skewed toward managers performing "audit" tasks rather than adjusters performing "workflow" tasks. Furthermore, the critical failure in the health-liability segment—the inability to explain recommendations to reviewers—suggests a fundamental gap in product utility (explainability) that no amount of "enablement" or "event tracking" will fix.

The Claim File Review is the only proposal that addresses the *ground truth* of the value proposition. By inspecting whether suggestions are accepted, overridden, or impossible to explain, you move from "proxy metrics" (usage/bookings) to "value metrics" (utility). This provides the necessary evidence to determine if DraftPath is a scalable product or a sales tool that has reached its ceiling.

**The strongest reason against it:**
It is the slowest and most labor-intensive of the validation tests. Unlike the Usage Quality Sprint (which is automated) or the Commercial Cleanroom (which leverages existing sales motions), a file review requires manual qualitative analysis. With the board locking the budget in twelve days, this method provides a "deep dive" into a small sample rather than a "wide view" of the entire install base, risking a conclusion based on an unrepresentative set of files.

**Observable evidence that would change my mind:**
If the "Commercial Cleanroom" results were to show that renewal rates and expansion intent remained identical between the group receiving the DraftPath pitch and the control group, it would prove that the product's perceived value is currently zero. In that case, I would shift the recommendation to "narrow the company plan around regulated health-liability workflows," as it would signal that the general B2B workflow is not a viable lever and only a highly specialized, compliant solution could save the product.

================  OUT-37  ================

---
anonymous_label: OUT-37
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: c8a44d97b35de4d45274b93edebcee7a9e4834a3d01f2531e7f127aa2e64d7df
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-37

**Recommendation: Run the Claim File Review.**

The current growth signals are contaminated by financial incentives (bundle pricing) and sales narratives (roadmap promises). Usage data is misleading because it captures manager-led demonstrations rather than adjuster-led productivity. The Claim File Review is the only intervention that isolates actual product utility from commercial pressure. By analyzing whether suggestions are accepted or overridden in a blind audit of existing files, you determine if the tool solves a problem or creates an administrative burden.

**Strongest reason against:**
This approach ignores the immediate commercial risk that the current expansion growth is a bubble. It does not test whether customers will pay for the product without discounts or roadmap promises, meaning you could validate that the tool is "useful" while remaining blind to the fact that it is not "marketable" at your current price point.

**Evidence that would change my mind:**
If the Commercial Cleanroom were modified to include a "forced-churn" analysis—specifically identifying if the two regional carriers who are already removing DraftPath did so because of a lack of utility or a lack of perceived value relative to price—I would switch to that. If the evidence shows that users *want* the tool but procurement is rejecting it, the problem is commercial; if they are rejecting it because it fails internal reviews (as seen in health-liability), the problem is the product.

================  OUT-38  ================

---
anonymous_label: OUT-38
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: cf5e2d7a2e8ca8c1e5b7c06564c7d2b949e05a6cdc31f08defcc5274beeba729
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-38

**Recommendation:** Run the Claim File Review.

**Reasoning:** The current success indicators are heavily contaminated. Expansion bookings were driven by pricing incentives rather than product value, and positive customer sentiment was elicited via a forward-looking roadmap pitch rather than current utility. Usage data is misleading; the increase is driven by managers performing retrospective audits, while front-line adjusters—the primary users—demonstrate a pattern of abandonment. The decrease in "wrong recommendation" tickets is likely a reporting shift to training channels rather than an improvement in accuracy.

The Claim File Review is the only intervention that prioritizes disconfirming evidence by looking at actual claim outcomes rather than proxy metrics. It reveals whether the software is actually solving a problem (accepted suggestions) or creating friction (overridden/unexplainable suggestions). In contrast, the Usage Quality Sprint tracks activity without quality, and the Commercial Cleanroom tests sales tactics rather than product-market fit.

**Strongest reason against:** This approach is slow and qualitative. It will not provide a statistically significant sample size across all segments in twelve days, potentially leaving the CEO with "anecdotal" evidence while Sales argues that the bundle pricing is a proven revenue lever.

**Evidence that would change my mind:** If you discover that the "unexplainable" actions in health-liability are not due to product failure, but are instead a result of adjusters lacking basic training on the existing tool. If evidence shows that users who override suggestions still complete their workflows 20% faster than those not using the tool, I would shift the recommendation to scaling DraftPath broadly.

================  OUT-39  ================

---
anonymous_label: OUT-39
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: d58d3509afbba2def5c338181ec7afb453e9dd60aab18ed027a124ccb159e1fc
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-39

**Recommendation:** Run the Claim File Review.

**Why:** The current "success" is an illusion created by lagging indicators and sales incentives. Expansion bookings are skewed by temporary bundle pricing, and usage spikes are driven by managers performing audits rather than adjusters performing work. Most critically, the "health-liability" segment—a regulated environment where explainability is a legal requirement—is already abandoning the tool. Before scaling or refining tracking (Usage Quality Sprint), you must determine if DraftPath provides actual utility or if it is simply "noise" that adjusters override. The Claim File Review is the only option that provides a ground-truth look at whether the product solves the core problem or if it is being bypassed in actual practice.

**Strongest Reason Against:** It is a manual, slow process that provides a small sample size. Unlike the Commercial Cleanroom or Usage Quality Sprint, it will not provide statistically significant data on revenue or broad user behavior across the entire customer base in time for the budget lock.

**Observable Evidence to Change My Mind:** If a deep dive into the "wrong recommendation" tickets (currently hidden in training channels) reveals that the errors are purely educational/UI-based rather than fundamental logic failures, I would pivot to the Usage Quality Sprint. If the errors are "how-to" rather than "what/why," then enablement is the bottleneck, not product utility.

================  OUT-40  ================

---
anonymous_label: OUT-40
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: d841514532f42f0456eff9d8ba7a151c498e1d80091b0f87d70c7f71ac6da094
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-40

I recommend that you commit to the **Claim File Review**.

### The Recommendation: Claim File Review
The company is currently experiencing a "false positive" signal. Your revenue growth is driven by temporary pricing incentives and sales narratives, not product value. Meanwhile, your usage data is skewed by managers performing "audit" behavior rather than adjusters performing "workflow" behavior.

The Claim File Review is the only option that penetrates this noise to find the **ground truth of utility**. By inspecting the actual claim files, you can determine if DraftPath is solving a problem or simply creating "administrative theater" where adjusters use the tool to satisfy managers but rewrite the output to actually do their jobs. This allows you to determine if the product needs a pivot (e.g., adding "explainability" for regulated health) or if the value proposition is fundamentally flawed before you lock in a budget based on phantom growth.

### The Strongest Reason Against It
**It is slow and qualitative.** Unlike the Usage Quality Sprint or the Commercial Cleanroom, this method does not provide a statistically significant "number" to show the board. It is labor-intensive and relies on small sample sizes, which may make it difficult to justify to a CEO who is currently riding a wave of 16% expansion growth and wants to "scale" the success.

### The Evidence That Would Change My Mind
I would switch my recommendation to the **Commercial Cleanroom** if you discovered that the "regional carrier" churn (the two accounts removing DraftPath) was driven primarily by a lack of budget/procurement issues rather than product dissatisfaction. If the product is fundamentally loved but the pricing model is broken, you don't need a file review—you need to test price elasticity and buyer intent.

================  OUT-41  ================

---
anonymous_label: OUT-41
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: d8de57f8eed53f92a70f9c0b21ec215a1e8168ffaf45bcff55964728b0368d02
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-41

I recommend that you commit to the **Claim File Review**.

### Reasoning
The current evidence is "entangled" by several distorting factors described in your artifacts:

1.  **Performance-Aware Attribution (BK-0048):** The executive team’s current praise—calling the product team "focused" and "disciplined"—is likely contaminated by the strong quarterly results (expansion bookings). This is a trait narrative triggered by an outcome, not independent evidence of strategic alignment.
2.  **False Progress Metrics (BK-0007):** The 39% usage increase is a "broad activity metric" that masks the reality. High frequency is driven by managers (not users) and initial rollout spikes, while front-line adjusters are reverting to manual notes. The "reduction" in support tickets is a reporting artifact (shifting to training channels), not an improvement in product quality.
3.  **Lack of Load-Bearing Diagnosis (BK-0001):** You do not yet know if the "problem" being solved is a lack of feature capability, a failure in user enablement, or a fundamental compliance gap (as seen in the health-liability segment).

The **Claim File Review** is the only option that provides a "load-bearing diagnosis." By inspecting actual claim files, you move past persuasive stories and activity dashboards to see if the product is actually solving the core challenge. It tests the critical uncertainty: *Is DraftPath providing value that adjusters trust and can defend, or is it a superficial tool being pushed by sales bundles?*

The other options are insufficient: the *Usage Quality Sprint* relies on the same activity metrics that are already misleading; the *Commercial Cleanroom* tests sales tactics rather than product value; and *scaling broadly* risks baking in a failure that is currently hidden by bundle pricing.

### The Strongest Reason Against This Recommendation
The Claim File Review is a qualitative, small-sample approach that will not provide the "hard" statistical confidence some board members crave. It is slower to execute than a dashboard sprint and may uncover "ugly" truths (e.g., that the product is fundamentally unusable in regulated segments) just as the budget is being locked, potentially creating friction with a leadership team currently riding a "high" from the quarterly results.

### Evidence That Would Change My Mind
I would change this recommendation to **"Narrow the company plan around regulated health-liability workflows"** if the Claim File Review reveals that the "impossible to explain" barrier is not a training issue, but a legal/regulatory requirement for auditability that DraftPath cannot currently meet. If the product is fundamentally incompatible with the highest-value, most regulated segment, scaling it broadly—even if "usable" in simpler segments—would be a strategic error.

================  OUT-42  ================

---
anonymous_label: OUT-42
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: dd3646b03cb27f6aac1fb613524f2ae79dbf41d22d8ebfb374f75666b6267be7
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-42

I recommend that you commit to the **Claim File Review**.

### The Reasoning
You are currently facing a "false positive" crisis. Your lagging indicators (bookings, renewals) are being artificially inflated by financial incentives (bundle pricing) and sales narratives (roadmap promises). Your leading indicators (usage) are misleading because they reflect manager-led enablement exercises rather than organic adjuster workflow.

The core risk is that DraftPath provides **perceived value** to the buyer (the manager/executive) but lacks **functional utility** for the user (the adjuster). In B2B workflow software, this gap is a leading indicator of churn.

The **Usage Quality Sprint** only tells you *that* users are leaving; it doesn't tell you *why*. The **Commercial Cleanroom** is a dangerous gamble that risks revenue and damages sales morale for the sake of data you can get more cheaply elsewhere. **Scaling broadly** based on current data is a recipe for a massive churn event in 12 months. **Narrowing to health-liability** is premature, as you don't yet know if the problem there is a product limitation or a regulatory reporting gap.

The **Claim File Review** is the only option that attacks the "ground truth." By auditing actual claim files, you move past vanity metrics and sentiment. You will discover if the "lack of wrong recommendation tickets" is because the tool is accurate, or because adjusters have simply stopped trusting it and are overriding it silently. This provides the necessary evidence to decide whether next year's budget should go toward *scaling* (if utility is high) or *pivoting* (if the logic is flawed).

### The Tradeoffs
By choosing the Claim File Review, you are displacing the **Usage Quality Sprint**.

**What you give up:** You sacrifice real-time, quantitative visibility into the "leaky bucket." You will not have a weekly dashboard showing exactly when adjusters drop off. You are trading *breadth* (knowing how many people quit) for *depth* (knowing exactly why the product failed a specific claim). You are betting that a qualitative understanding of "impossible to explain" actions is more valuable than a quantitative chart of declining return rates.

### The Strongest Reason Against This Recommendation
The Claim File Review is slow and manually intensive. While you are spending weeks auditing files, the "silent churn" happening in your regional carrier accounts will continue. Because this method doesn't provide a "hard number" as quickly as the Usage Quality Sprint, you may struggle to convince a commercially-driven executive team that the product is failing if the bookings numbers continue to look strong in the short term.

### Evidence That Would Change My Mind
I would switch my recommendation to the **Commercial Cleanroom** if you discover that your "bundle pricing" represents more than 50% of your expansion revenue. If the financial distortion is that severe, you no longer have a product problem—you have a pricing and sales integrity problem. In that case, the only way to save the company's valuation is to immediately stress-test whether anyone will pay a fair market price for DraftPath without the bundle.

================  OUT-43  ================

---
anonymous_label: OUT-43
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: ec8b6c1fe163c23ab751830736ceb0f19803f2326be31cea813f4c431730dae2
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-43

I recommend that you commit to the **Claim File Review**.

### The Recommendation
You should reject the "strong quarter" narrative and instead perform a deep-dive audit of actual claim files from renewed accounts. You must determine if DraftPath is providing genuine utility to the adjuster or if it has simply become a "compliance theater" tool used by managers for enablement meetings.

### The Why
Your current growth is an illusion created by **incentive misalignment** and **survivorship bias**.
1. **Financials are skewed:** The expansion bookings are driven by a temporary bundle price (a pricing tactic), not necessarily product value.
2. **Usage is deceptive:** A 39% increase in usage is meaningless if the activity is "rerunning closed samples" (training/audit) rather than active claims handling.
3. **The "Silent Churn" is real:** Regional carriers are already opting out, and health-liability adjusters are abandoning the tool because it fails the "explainability" test—a critical failure in a regulated industry.

The *Usage Quality Sprint* only measures *if* they use it; the *Commercial Cleanroom* only measures if they *pay* for it. Only the *Claim File Review* reveals *why* they use it (or don't). If adjusters are manually rewriting every suggestion, you aren't scaling a product; you are scaling a liability that will lead to mass churn once the bundle pricing expires.

### The Strongest Reason Against It
This is a slow, manual, and qualitative process. Unlike the Usage Quality Sprint (which provides a dashboard) or the Cleanroom (which provides hard revenue data), the Claim File Review will not give the board a "green light" metric in twelve days. It risks delivering "bad news" that contradicts the current executive euphoria, potentially making the product team look like they are stalling momentum during a winning streak.

### Evidence That Would Change My Mind
I would switch my recommendation to the **Commercial Cleanroom** if you could prove that the "explainability" issue in health-liability is a fringe edge case rather than a systemic flaw. If the data showed that 80%+ of non-health-liability adjusters are accepting DraftPath suggestions *without* manual rewrites, then the product is fundamentally sound and your only remaining risk is pricing strategy—making the Cleanroom the highest-leverage move.

================  OUT-44  ================

---
anonymous_label: OUT-44
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: eef5ae1e70fc6a62ba0bc1a277f6c58ebe64d8f9fe9f6053f2e6c972e33590b5
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-44

**Recommendation**
Commit to the Claim File Review.

**Reasoning**
The current positive indicators are contaminated by financial incentives and behavioral bias. Expansion bookings were driven by temporary pricing bundles rather than perceived value, and customer enthusiasm was elicited after sales teams signaled that the feature is the future of the roadmap. Usage data is misleading; it reflects managers auditing past files for training purposes rather than adjusters using the tool for active claims work. Furthermore, the decline in "wrong recommendation" tickets is likely a reporting shift to training channels rather than an improvement in accuracy.

The Claim File Review is the only intervention that targets independent evidence by looking at the actual work product (the claim file) rather than self-reported sentiment or surface-level activity logs. It reveals the "silent churn" happening in health-liability and among front-line adjusters who abandon the tool once manager supervision ends. While a usage sprint tracks *if* people return, and a commercial cleanroom tracks *if* they pay, only the file review reveals *why* the tool is being overridden or ignored.

**Strongest Reason Against**
This approach provides a lagging indicator of value and does not immediately protect the revenue pipeline or solve the immediate friction in regulated segments. It identifies the failure point but does not test a specific commercial or technical fix, potentially delaying a pivot until after the budget is locked.

**Evidence That Would Change This Recommendation**
If the "Commercial Cleanroom" results (should they be run informally) showed that renewal rates and expansion intent remained stable even without bundle pricing or roadmap pitches, it would prove the value proposition is strong enough to withstand a lack of incentives. In that case, the priority would shift from diagnosing value (File Review) to optimizing delivery (Usage Quality Sprint).

================  OUT-45  ================

---
anonymous_label: OUT-45
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: f102a1188977e1f702360f3c9e5470a9ac5675769cae67c744197edf812a9bfd
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-45

**Recommendation:** Run the Claim File Review.

**Why:** Your current success is a "mirage" created by lagging indicators and incentive structures. The expansion bookings are driven by temporary pricing (financial engineering), not necessarily value delivery. More critically, the usage data is deceptive: high frequency is driven by managers (supervisors) rather than the primary users (adjusters), and front-line adoption is collapsing after 48 hours.

The "Usage Quality Sprint" tracks *if* people use the tool, but you already know they aren't using it correctly. The "Commercial Cleanroom" tracks *if* people will pay, but you cannot fix the product based on a "no." The Claim File Review is the only option that exposes the *why* behind the failure. It targets the "Jobs to be Done" (as conceptualized in *Competing Against Luck*) by revealing where the product fails to provide a "job-ready" output that adjusters can defend to reviewers—specifically in the health-liability segment. You must determine if DraftPath is providing actual utility or if it is merely a "theatre of productivity" for managers before you scale it or pivot the company plan.

**The strongest reason against this:** It is the slowest and most labor-intensive of the validation tests. While the board locks the budget in twelve days, a manual file review provides qualitative depth but lacks the statistical "cleanliness" and speed of an analytics sprint or a sales A/B test. It risks providing "anecdotal" evidence that the executive team—currently riding a high of strong quarterly numbers—may dismiss as non-representative.

**Observable evidence that would change my mind:** If the "Commercial Cleanroom" data revealed that customers were willing to pay a premium for DraftPath *even without* the bundle pricing and roadmap promises, it would suggest that the perceived value is high enough to override current usability friction. In that case, I would switch the recommendation to "Scale DraftPath Broadly," as it would indicate the market is pulling the product through despite its flaws.

================  OUT-46  ================

---
anonymous_label: OUT-46
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: f36da6ec53180928b6768ed995cb79da27520cf70e05044166d33633fefe719c
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-46

I recommend that you commit to the **Claim File Review**.

### The Recommendation
The executive team is currently operating on "noisy" signals. Your expansion bookings are inflated by temporary pricing (financial noise), your usage spikes are driven by managers simulating scenarios rather than adjusters executing work (behavioral noise), and your support tickets have simply migrated channels (operational noise).

The **Claim File Review** is the only option that penetrates this noise to find the "ground truth": whether DraftPath actually solves a problem in the claim file. By auditing accepted vs. overridden suggestions, you move from measuring *activity* (which can be coerced by managers) to measuring *utility* (which is required for long-term retention). This provides the necessary evidence to decide if you should scale, pivot toward health-liability, or rebuild the logic entirely before the budget is spent on a product that users are currently "performing" for their bosses.

### The Strongest Reason Against It
The Claim File Review is a slow, manual qualitative process that provides a small sample size. Unlike the Usage Quality Sprint or Commercial Cleanroom, it does not produce "hard" financial or behavioral metrics that a Board typically prefers. By choosing this, you sacrifice the ability to immediately quantify the revenue impact of the bundle pricing or the precise drop-off rate of adjusters, potentially leaving the CEO feeling they lack a "statistically significant" number to present to the board.

### The Evidence That Would Change My Mind
I would switch my recommendation to the **Commercial Cleanroom** if you discovered that the "regional carrier" churn (the two accounts planning to remove DraftPath) was not based on product utility, but specifically on a pricing misalignment. If the primary risk is that you have accidentally trained the market to only value DraftPath at a discounted bundle price, then the problem is a commercial positioning failure rather than a product-market fit failure. In that specific case, validating the price elasticity via the Cleanroom becomes more urgent than validating the workflow utility.

================  OUT-47  ================

---
anonymous_label: OUT-47
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: fce0d65ef288c4773bdd806bd8e8ec1146e3cb619899ebc9180d705415373442
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-47

**Recommendation**
Run the Claim File Review.

**Reasoning**
The current growth indicators are heavily contaminated by financial incentives and sales narratives. The rise in expansion bookings is tied to temporary pricing bundles rather than perceived value, and positive customer feedback was elicited after sales promised a specific roadmap. Furthermore, the usage spike is misleading; it is driven by managers auditing closed files for training rather than adjusters utilizing the tool for live claims. The most critical signal is the "silent churn" from regional carriers and the abandonment by health-liability adjusters due to a lack of explainability.

The Usage Quality Sprint focuses on surface-level metrics (return rates) that may still be skewed by manager audits. The Commercial Cleanroom tests price sensitivity and sales pitches, but not whether the product actually solves a problem. Only the Claim File Review looks at the actual work product—the claim file—to see if the software's output is being used, ignored, or rewritten. This reveals whether the tool provides genuine utility or if it is merely a "theatrical" feature that looks good in a demo but fails in production.

**Strongest Reason Against**
This approach is labor-intensive and provides a small sample size compared to automated analytics. It risks identifying specific failures in a few accounts that may not represent the broader user base, potentially leading to an over-correction based on anecdotal evidence from a handful of adjusters.

**Evidence That Would Change My Recommendation**
If the "wrong recommendation" tickets in the training channel are analyzed and found to be negligible, and if data shows that front-line adjusters in non-regulated segments have a high "save rate" (keeping the proposed plan without edits) after the initial two-day drop-off, I would shift to scaling the product broadly. This would indicate that the friction is limited to a specific segment and that the core value proposition is already validated.

================  OUT-48  ================

---
anonymous_label: OUT-48
case_id: halo-evidence-vs-diagnosis-validation-v9
benchmark_version: halo-evidence-vs-diagnosis-validation-v9-v1
output_sha256: fdfad510e1a4d27467c0928851aa48f7cf7a5345063120e5227a3cd95b20c1c7
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-48

I recommend that you commit to the **Claim File Review**.

### The Rationale
Your current "strong quarter" is an illusion created by lagging indicators and sales incentives. Expansion bookings are driven by a temporary bundle price (financial incentive) and roadmap promises (future hope), not realized value.

The usage data is a "vanity metric": managers are using the tool for audits/enablement, but front-line adjusters—the actual users who drive long-term retention—are abandoning it. The "drop in support tickets" is a reporting artifact (tickets moved to training), not a quality improvement. Most critically, in the health-liability segment, the product fails the "explainability" test, which is a fatal flaw in regulated industries.

You are facing a classic **Product-Market Fit gap**: the buyers (executives/managers) like the *idea* of DraftPath, but the users (adjusters) find it impractical or risky. If you scale now, you will build a massive "churn cliff" for next year. The Claim File Review is the only option that provides ground-truth evidence of whether the product actually solves the problem or if it is simply a "manager’s toy" that adjusters ignore.

### The Strongest Reason Against It
The Claim File Review is slow and qualitative. Unlike the Usage Quality Sprint (which provides a dashboard) or the Commercial Cleanroom (which tests pricing), the File Review requires manual effort and does not provide a statistically significant "number" to show the board. In twelve days, you will have a methodology, not a result, which may make the executive team feel you are slowing down the momentum of a "strong quarter."

### Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discovered that the "abandonment" by front-line adjusters was purely a training issue rather than a functional one. Specifically, if the "enablement requests" in the support channel revealed that adjusters *want* to use the tool but simply don't know how, then the problem is GTM/Enablement (which a Cleanroom tests) rather than Product Value (which the File Review tests). However, the health-liability "explainability" issue suggests the problem is deep in the product logic, making the File Review essential.
